Statistical Analysis Plan I4V-MC-JAHLv2

Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis

NCT03334396

Approval Date: 16-Jan-2019
1. Statistical Analysis Plan:
I4V-MC-JAHL: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis

BREEZE-AD1

Confidential Information

The information contained in this document is confidential and the information contained within it may not be reproduced or otherwise disseminated without the approval of Eli Lilly and Company or its subsidiaries.

Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release. In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.

Baricitinib (LY3009104) Atopic Dermatitis

Study I4V-MC-JAHL (NCT03334396) is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, outpatient, 25-week study designed to evaluate the efficacy and safety of baricitinib 1-mg, 2-mg, and 4-mg in adult patients with moderate to severe atopic dermatitis.

Eli Lilly and Company
Indianapolis, Indiana USA 46285
Protocol I4V-MC-JAHL
Phase 3

Statistical Analysis Plan Version 1 electronically signed and approved by Lilly: 26-March-2018
Statistical Analysis Plan Version 2 electronically signed and approved by Lilly on date provided below.

Approval Date: 16-Jan-2019 GMT
2. Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Statistical Analysis Plan: I4V-MC-JAHL: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis</td>
<td>1</td>
</tr>
<tr>
<td>2. Table of Contents</td>
<td>2</td>
</tr>
<tr>
<td>3. Revision History</td>
<td>7</td>
</tr>
<tr>
<td>4. Study Objectives</td>
<td>8</td>
</tr>
<tr>
<td>4.1. Primary Objective</td>
<td>8</td>
</tr>
<tr>
<td>4.2. Secondary Objectives</td>
<td>8</td>
</tr>
<tr>
<td>4.2.1. Key Secondary Objectives</td>
<td>8</td>
</tr>
<tr>
<td>4.2.2. Other Secondary Objectives</td>
<td>9</td>
</tr>
<tr>
<td>4.3. Exploratory Objectives</td>
<td>10</td>
</tr>
<tr>
<td>5. Study Design</td>
<td>11</td>
</tr>
<tr>
<td>5.1. Summary of Study Design</td>
<td>11</td>
</tr>
<tr>
<td>5.2. Method of Assignment to Treatment</td>
<td>12</td>
</tr>
<tr>
<td>6. A Priori Statistical Methods</td>
<td>14</td>
</tr>
<tr>
<td>6.1. Determination of Sample Size</td>
<td>14</td>
</tr>
<tr>
<td>6.2. General Considerations</td>
<td>14</td>
</tr>
<tr>
<td>6.2.1. Analysis Populations</td>
<td>14</td>
</tr>
<tr>
<td>6.2.2. Definition of Baseline and Postbaseline Measures</td>
<td>15</td>
</tr>
<tr>
<td>6.2.3. Analysis Methods</td>
<td>17</td>
</tr>
<tr>
<td>6.2.4. Derived Data</td>
<td>19</td>
</tr>
<tr>
<td>6.3. Covariate Adjustment</td>
<td>20</td>
</tr>
<tr>
<td>6.4. Handling of Dropouts or Missing Data</td>
<td>20</td>
</tr>
<tr>
<td>6.4.1. Nonresponder Imputation</td>
<td>22</td>
</tr>
<tr>
<td>6.4.2. Mixed Model for Repeated Measures</td>
<td>22</td>
</tr>
<tr>
<td>6.4.3. Modified Last Observation Carried Forward</td>
<td>22</td>
</tr>
<tr>
<td>6.4.4. Placebo Multiple Imputation</td>
<td>23</td>
</tr>
<tr>
<td>6.4.5. Tipping Point Analyses</td>
<td>24</td>
</tr>
<tr>
<td>6.5. Multicenter Studies</td>
<td>26</td>
</tr>
<tr>
<td>6.6. Multiple Comparisons/Multiplicity</td>
<td>26</td>
</tr>
<tr>
<td>6.7. Patient Disposition</td>
<td>31</td>
</tr>
<tr>
<td>6.8. Patient Characteristics</td>
<td>32</td>
</tr>
<tr>
<td>6.8.1. Demographics</td>
<td>32</td>
</tr>
<tr>
<td>6.8.2. Baseline Disease Characteristics</td>
<td>32</td>
</tr>
</tbody>
</table>
6.8.3. Historical Illness and Pre-existing Conditions ......................................................33
6.9. Treatment Compliance .........................................................................................33
6.9.1. Rescue Treatment .............................................................................................34
6.10. Previous and Concomitant Therapy ....................................................................35
6.11. Efficacy Analyses ...............................................................................................35
6.11.1. Primary Outcome and Methodology .................................................................42
6.11.2. Secondary and Exploratory Efficacy Analyses ................................................42
6.11.3. Sensitivity Analyses ..........................................................................................43
6.13. Bioanalytical and Pharmacokinetic/Pharmacodynamic Methods .........................45
6.14.1. Extent of Exposure .............................................................................................45
6.14.2. Adverse Events ...................................................................................................46
6.14.2.2. Serious Adverse Event Analyses .................................................................47
6.14.2.3. Other Significant Adverse Events ..............................................................48
6.14.2.4. Criteria for Notable Patients ........................................................................48
6.14.3. Clinical Laboratory Evaluation ........................................................................48
6.14.4. Vital Signs and Other Physical Findings ..........................................................49
6.14.5. Special Safety Topics, including Adverse Events of Special Interest ................49
6.14.5.1. Abnormal Hepatic Tests ................................................................................50
6.14.5.2. Hematologic Changes ...................................................................................51
6.14.5.3. Lipids Effects ................................................................................................52
6.14.5.4. Renal Function Effects ................................................................................53
6.14.5.5. Elevations in Creatine Phosphokinase (CPK) ................................................53
6.14.5.6. Infections ......................................................................................................54
6.14.5.7. Major Adverse Cardiovascular Events (MACE) and Other Cardiovascular Events ..................................................................................................................55
6.14.5.8. Venous and Pulmonary Artery Thromboembolic (VTE) Events ....................56
6.14.5.9. Arterial Thromboembolic (ATE) Events ........................................................57
6.14.5.10. Malignancies ..............................................................................................58
6.14.5.11. Allergic Reactions/Hypersensitivities ..........................................................59
6.14.5.13. Columbia Suicide Severity Rating Scale ....................................................59
6.15. Subgroup Analyses ...............................................................................................59
6.16. Protocol Deviations........................................................................................................72
6.17. Interim Analyses and Data Monitoring ........................................................................73
  6.17.1. Interim Analysis Plan .........................................................................................73
6.18. Planned Exploratory Analyses .....................................................................................74
6.19. Annual Report Analyses .............................................................................................74
6.20. Clinical Trial Registry Analyses ..................................................................................74
7. Unblinding Plan ................................................................................................................75
8. References ............................................................................................................................76
Table of Contents

<table>
<thead>
<tr>
<th>Table</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table JAHL.5.1. Geographic Regions for Stratification</td>
<td>13</td>
</tr>
<tr>
<td>Table JAHL.6.1. Imputation Techniques for Various Variables</td>
<td>21</td>
</tr>
<tr>
<td>Table JAHL.6.2. Seed Values for Multiple Imputation</td>
<td>24</td>
</tr>
<tr>
<td>Table JAHL.6.3. Seed Values for Imputation</td>
<td>26</td>
</tr>
<tr>
<td>Table JAHL.6.4. Description and Derivation of Primary, Secondary and Exploratory Efficacy Outcomes</td>
<td>37</td>
</tr>
<tr>
<td>Table JAHL.6.5. Description of Primary, Secondary and Exploratory Efficacy Analyses</td>
<td>40</td>
</tr>
<tr>
<td>Table JAHL.6.6. Description and Derivation of Health Outcomes and Quality-of-Life Measures</td>
<td>44</td>
</tr>
<tr>
<td>Table JAHL.6.7. Description of Health Outcomes and Quality-of-Life Measures Analyses</td>
<td>51</td>
</tr>
<tr>
<td>Table JAHL.6.8. Categorical Criteria for Abnormal Treatment-Emergent Blood Pressure and Pulse Measurement, and Categorical Criteria for Weight Changes for Adults</td>
<td>60</td>
</tr>
</tbody>
</table>
## Table of Contents

<table>
<thead>
<tr>
<th>Figure</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure JAHL.5.1. Illustration of study design for Clinical Protocol I4V-MC-JAHL.</td>
<td>12</td>
</tr>
<tr>
<td>Figure JAHL.6.1. Illustration of graphical multiple testing procedure with initial $\alpha$ allocation and weights.</td>
<td>30</td>
</tr>
</tbody>
</table>
3. Revision History

Statistical Analysis Plan (SAP) Version 1 is based on Protocol I4V-MC-JAHL(a) and was approved prior to the production transfer for the first DMC meeting. SAP Version 2 was approved prior to the final database lock and includes the following changes:

- added additional exploratory objective for TCS use
- added follow-up population definition
- removed details included in the standards
- updated daily diaries to use an interval mean weekly score
- updated baseline and post-baseline algorithm for actigraphy to use time
- updated frequency of itch and skin pain to use 28-day visit intervals
- added estimand language
- added additional details for MMRM and ANCOVA
- added time to event analysis
- added baseline value to logistic regression model
- added seed values for tipping point
- updated diagnosis age group categories
- updated definition for deriving age and diagnosis age
- added BMI category, weight category and PGI-S-AD to baseline summaries
- added 2 cyclosporine subset definitions and revised existing subset definition; added to baseline summaries
- updated seed values for pMI
- added overall summary of rescue therapies
- clarified sensitivity analyses for PPS, pMI and tipping point in Tables JAHL.6.4 and JAHL.6.6
- removed comparisons in Table JAHL.6.6 when not needed
- updated mapping of ET visits to closest, not next visit
- added definition for safety baseline for clarity
- added sensitivity analysis for safety to censor on last dose of study drug for rescue to systemics
- update exposure ranges from weeks to days
- removed temporary interruption of study drug to AE or lab from overview of AE table
- removed mention of incidence-rates, including exposure adjusted incidence rates
- updated to refer to compound level safety standards instead of PSAP
- added PT for malignancy
- provided clarity that CSSRS summary will be created when positive responses happen during treatment
- updated subgroup analyses
- Added a Cox proportional hazard (CPH) model of minimum time (in days) to 4-point itch reduction with effects for treatment, region (where applicable), baseline mean itch, and disease severity to section 6.2.3
- Updated the graphical approach
4. Study Objectives

4.1. Primary Objective
The primary objective of this study is to test the hypothesis that baricitinib 4-mg once daily (QD) or baricitinib 2-mg QD is superior to placebo in the treatment of patients with moderate to severe atopic dermatitis (AD), as assessed by the proportion of patients achieving the validated Investigator’s Global Assessment for AD (vIGA-AD, referred to throughout the SAP as IGA) of 0 or 1 with a ≥2-point improvement at Week 16.

In particular, the associated estimand for this objective is to measure the effect of therapy with baricitinib as assed by the proportion of patients with a response of IGA 0 or 1 at Week 16 assuming treatment response disappears after patients are rescued or discontinue from the study or treatment. See Sections 6.4.1 and 6.11.1 on how this estimand handles outcomes after the occurrence of any intercurrent event through nonresponder imputation (NRI).

4.2. Secondary Objectives

4.2.1. Key Secondary Objectives
These are prespecified objectives that will be adjusted for multiplicity.

<table>
<thead>
<tr>
<th>Objectives</th>
<th>Endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td>To test the hypothesis that baricitinib 1-mg QD is superior to placebo in treatment of patients with moderate to severe AD.</td>
<td>• Proportion of patients achieving IGA of 0 or 1 with a ≥2-point improvement at Week 16</td>
</tr>
</tbody>
</table>
| To compare the efficacy of baricitinib 1-mg QD, 2-mg QD, or 4-mg QD to placebo in AD during the 16-week double-blind placebo-controlled treatment period as measured by improvement in signs and symptoms of AD. | • Proportion of patients achieving EASI75 at 16 weeks  
• Proportion of patients achieving EASI90 at 16 weeks  
• Percent change from baseline in EASI score at 16 weeks  
• Proportion of patients achieving SCORAD75 at 16 weeks |
| To compare the efficacy of baricitinib 1-mg QD, 2-mg QD, or 4-mg QD to placebo in AD during the 16-week double-blind placebo-controlled treatment period as assessed by patient-reported outcome measures. | • Proportions of patients achieving a 4-point improvement from baseline in Itch NRS at 1 week, 2 weeks, 4 weeks, and 16 weeks  
• Mean change from baseline in the score of Item 2 of the ADSS at 1 week and 16 weeks  
• Mean change from baseline in Skin Pain NRS at 16 weeks |
### 4.2.2. Other Secondary Objectives

These are prespecified objectives that will not be adjusted for multiplicity.

<table>
<thead>
<tr>
<th>Objectives</th>
<th>Endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td>To test the hypothesis that baricitinib 1-mg QD, 2-mg QD, or 4-mg QD is superior to placebo in the treatment of patients with moderate to severe AD.</td>
<td>• Proportion of patients achieving IGA of 0 or 1 with a ≥2-point improvement at Week 4</td>
</tr>
<tr>
<td>To compare the efficacy of baricitinib 1-mg QD, 2-mg QD, or 4-mg QD to placebo in AD during the 16-week double-blind placebo-controlled period as measured by physician-assessed signs and symptoms of AD.</td>
<td>• Proportion of patients achieving EASI50 at 16 weeks&lt;br&gt;• Proportion of patients achieving IGA of 0 at 16 weeks&lt;br&gt;• Mean change from baseline in SCORAD at 16 weeks&lt;br&gt;• Proportion of patients achieving SCORAD90 at 16 weeks&lt;br&gt;• Mean change from baseline in BSA affected at 16 weeks&lt;br&gt;• Proportion of patients developing skin infections requiring antibiotic treatment by Week 16</td>
</tr>
<tr>
<td>To compare the efficacy of baricitinib 1-mg QD, 2-mg QD, or 4-mg QD to placebo in AD during the 16-week, double-blind, placebo-controlled treatment period as assessed by patient-reported outcome/QoL measures.</td>
<td>• Percent change from baseline in Itch NRS at 1 week and 16 weeks&lt;br&gt;• Mean change from baseline in Itch NRS at 4 weeks and 16 weeks&lt;br&gt;• Mean change from baseline in the total score of the POEM at 16 weeks&lt;br&gt;• Mean change in the PGI-S-AD scores at 16 weeks&lt;br&gt;• Mean change from baseline in HADS at 16 weeks&lt;br&gt;• Mean change in the DLQI scores at 16 weeks&lt;br&gt;• Mean change in the WPAI scores at 16 weeks&lt;br&gt;• Mean change in the EQ-5D-5L scores at 16 weeks</td>
</tr>
</tbody>
</table>
4.3. **Exploratory Objectives**

The exploratory objectives of this study are the following:

<table>
<thead>
<tr>
<th>Objectives/Endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean change from baseline in nocturnal itch assessed by actigraphy device at 1 week and 4 weeks</td>
</tr>
<tr>
<td>Frequency of patient-reported “no itch” (Itch NRS score = 0) days from daily diaries from Week 12 to Week 16</td>
</tr>
<tr>
<td>Frequency of patient-reported “no pain” (Skin Pain NRS score = 0) days from daily diaries from Week 12 to Week 16</td>
</tr>
<tr>
<td>Mean change from baseline in the score of Item 1 of the ADSS at 1 week and 16 weeks</td>
</tr>
<tr>
<td>Mean change from baseline in the score of Item 3 of the ADSS at 1 week and 16 weeks</td>
</tr>
<tr>
<td>To evaluate changes from baseline in immunoglobulin E levels during the study</td>
</tr>
<tr>
<td>To evaluate changes from baseline in eosinophil levels during the study</td>
</tr>
<tr>
<td>To characterize baricitinib pharmacokinetics in the AD population and explore relationships between baricitinib exposure and study endpoints</td>
</tr>
<tr>
<td>To assess time to 4-pt itch reduction during the first 14 days after initiation of treatment</td>
</tr>
<tr>
<td>To assess time to improvement in Skin Pain during the first 14 days after the initiation of treatment</td>
</tr>
<tr>
<td>To assess the use of rescue therapy through the weight of sponsor provided topical corticosteroid and number of days not using rescue therapy</td>
</tr>
</tbody>
</table>
5. Study Design

5.1. Summary of Study Design

Study I4V-MC-JAHL (JAHL) is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, outpatient study evaluating the efficacy and safety of baricitinib 1-mg once daily (QD), 2-mg QD, and 4-mg QD as compared to placebo in adult patients with moderate to severe AD. The study is divided into 3 periods, a 5-week Screening period, a 16-week Double-Blinded Treatment period, and a 4-week Post-Treatment Follow-Up period. For those patients who complete the 16-week treatment period, there is an option to participate in the long-term extension study I4V-MC-JAHN (JAHN).

Approximately 600 patients ≥18 years of age who have responded inadequately to or who are intolerant to topical therapy will be randomized at a 2:1:1:1 ratio to receive placebo QD, baricitinib 1-mg QD, baricitinib 2-mg QD, or baricitinib 4-mg QD (240 patients in the placebo group; 120 patients in each baricitinib treatment group).

Study JAHL will consist of 3 periods:

- Period 1: Screening period is between 8 and 35 days prior to Week 0 (Visit 2)
- Period 2: Double-Blind, Placebo-Controlled Treatment period from Week 0 (Visit 2) through Week 16 (Visit 8)
- Period 3: Post-Treatment Follow-Up period from last treatment visit at Week 16 (Visit 8) or Early Termination Visit (ETV) to approximately 28 days after the last dose of investigational product

Figure JAHL.5.1 illustrates the study design. The blinding procedure is described in the Protocol.
Figure JAHL.5.1. Illustration of study design for Clinical Protocol I4V-MC-JAHL.

Abbreviations: AD = atopic dermatitis; eGFR = estimated glomerular filtration rate; PPD = purified protein derivative; QD = once daily; V = visit; W = week.

a Applicable to patients taking topical treatments (excluding emollients) or systemic treatments for AD at the time of screening.

b For patients randomized to the 4-mg once daily dose who have renal impairment (defined as eGFR <60 mL/min/1.73 m²), the baricitinib dose will be 2-mg once daily.

c Patients for whom PPD skin test for the evaluation of tuberculosis infection was performed at V1 must return and PPD test must be read 48 to 72 hours after Visit 1 (post-PPD).

d Occurs approximately 28 days after the last dose of investigational product. Not required for those patients entering the long-term extension study JAHN.

5.2. Method of Assignment to Treatment

Patients who meet all criteria for enrollment will be randomized in a 2:1:1:1 ratio (placebo, baricitinib 1-mg; baricitinib 2-mg; baricitinib 4-mg) to double-blind treatment at Visit 2 (Week 0). Randomization will be stratified by geographic region (Europe [EU], Japan [JPN], rest-of-world [ROW]) and disease severity at baseline (IGA 3 vs. 4). Assignment to treatment groups will be determined by a computer-generated random sequence using an interactive web-response system (IWRS). The IWRS will be used to assign blister packs, each containing double-blind investigational product tablets to each patient, starting at Visit 2 (Week 0), and at each visit up to and including Visit 7 (Week 12). Site personnel will confirm that they have located the correct blister packs by entering a confirmation number found on the blister packs into the IWRS.
This study will be conducted internationally in multiple sites. Table JAHL.5.1 describes how regions will be defined for stratification. Regions may be combined for statistical analyses in the case when one of the region strata fails to meet the required minimum number of 30 patients. The 2 region strata with the least number of patients will then be pooled.

Table JAHL.5.1. Geographic Regions for Stratification

<table>
<thead>
<tr>
<th>Region</th>
<th>Countries</th>
</tr>
</thead>
<tbody>
<tr>
<td>Europe</td>
<td>Czech Republic, Denmark, France, Germany, Italy</td>
</tr>
<tr>
<td>Japan</td>
<td>Japan</td>
</tr>
<tr>
<td>Rest of World</td>
<td>India, Mexico, Russia, Taiwan</td>
</tr>
</tbody>
</table>
6. A Priori Statistical Methods

6.1. Determination of Sample Size

Study JAHL will aim to enroll approximately 600 patients ≥18 years of age. The proposed sample size will ensure a >90% power to detect any difference between the baricitinib 4-mg and placebo treatment groups and the baricitinib 2-mg and placebo treatment groups, each using a 2-sided alpha of 0.05, assuming 10% placebo, 25% baricitinib 2-mg, and 30% baricitinib 4-mg response rates for the primary endpoint. The assumptions are based on what was observed in the Phase 2 Study (I4V-MC-JAHG). The proposed end point of IGA 0 or 1 represents patients whose AD is clear or almost clear from a baseline of moderate or severe disease. The anticipated effect size represents 3 times more patients achieving this benefit compared to placebo, which in discussion with therapeutic experts, is of a magnitude that is considered clinically relevant.

Sample size and power estimates were obtained from nQuery® Advisor 7.0.

6.2. General Considerations

This plan describes a priori statistical analyses for efficacy, health outcomes, and safety that will be performed.

Statistical analysis of this study will be the responsibility of Eli Lilly and Company (Lilly). The statistical analyses will be performed using SAS® Version 9.4 or higher.

Not all displays described in this SAP will necessarily be included in the clinical study report (CSR). Not all displays will necessarily be created as a “static” display. Some may be incorporated into interactive display tools instead of or in addition to a static display. Any display described in this SAP and not included in the CSR will be available upon request.

Statistical tests of treatment effects and confidence intervals (CIs) will be performed at a 2-sided significance level of 0.05, unless otherwise stated (e.g., graphical multiple testing strategy in Section 6.6).

Data collected at early termination visits will be mapped to the closest scheduled visit number for that patient if it falls within the visit window as discussed in Section 6.2.2. For by-visit summaries, only visits in which a measure was scheduled to be collected will be summarized. Any unscheduled visit data will be included at the patient-level listings. However, the data will still be used in other analyses, including shift analyses for safety analytes, change from baseline using modified last observation carried forward (mLOCF) for efficacy analyses, and other categorical analyses including safety.

6.2.1. Analysis Populations

**Intent-to-treat (ITT) population:** The ITT population analysis set is defined as all randomized patients.

**Per-protocol Set (PPS):** PP subset of the ITT analysis set will include those patients who do not have any significant or important protocol violations. Qualifications for and identification of
significant or important protocol violations will be determined while the study remains blinded, prior to database lock.

**Follow-up population:** The follow-up population is defined as patients who entered the follow-up period.

Unless otherwise specified, the efficacy and health outcome analyses will be conducted on the ITT population (Gillings and Koch 1991), which seeks to preserve the benefits of randomization and avoid selection bias. Patients will be analyzed according to the treatment to which they were randomized. In addition, the analyses of primary and key secondary endpoints will be repeated using the PPS population.

**Safety population:** The safety population is defined as all randomized patients who receive at least 1 dose of investigational product and who did not discontinue from the study for the reason ‘Lost to Follow-up’ at the first postbaseline visit.

Safety analyses will be performed using the safety population. Patients will be analyzed according to the treatment regimen to which they were assigned. Analyses of the safety endpoints, many of which are incidence based, will include all patients in the safety population, unless specifically stated otherwise.

In the rare situation where a patient is Lost to Follow-up at the first postbaseline visit, but some safety data exists (e.g., unscheduled laboratory assessments) after first dose of study drug, a listing of the data or a patient profile will be provided, when requested.

6.2.2. **Definition of Baseline and Postbaseline Measures**

The baseline value for efficacy and health outcomes variables measured at scheduled visits is defined as the last non-missing measurement on or prior to the date of first study drug administration (expected at Week 0, Visit 2).

The baseline value for the daily diary assessments (Itch NRS, ADSS, Skin Pain NRS, PGI-SAD) and for the actigraphy analyses period is the mean of the non-missing assessments in the 7 days prior to the date of first study drug administration (expected at Week 0, Visit 2).

If there are less than 4 non-missing assessments in the baseline diary window, the interval lower bound can be extended up to 7 additional days, one day at a time, to obtain the most recent 4 non-missing values. If there are not at least 4 non-missing assessments in the baseline period, the baseline mean is missing.

The baseline value for actigraphy assessments is the mean of the non-missing assessments in the 7 days prior to the date and time of first study drug administration. The baseline mean for actigraphy variables require there be at least 4 non-missing measurements occurring in at least 4 separate 24-hour increments in the 7 days prior to the date and time of first study drug administration. If this condition is not satisfied, an expanded window of up to 14 days (336 hours) prior to first study drug administration may be utilized in order to obtain the most recent 4 non-missing measurements, occurring in 4 separate 24-hour increments. If there are not at least 4 non-missing assessments collected in the baseline period, the baseline mean will be designated
as missing. Other definitions of baseline value, such as the last measurement on or prior to rescue, may be used to conduct additional supporting analyses.

Baseline for the safety analyses is defined as the last non-missing scheduled (planned) measurement on or prior to the date of first study drug administration for continuous measures by-visit analyses and non-missing measurements on or prior to the date of first study drug administration for all other analyses.

Postbaseline measurements are collected after study drug administration through Week 16 (Visit 8) or early discontinuation visit. Efficacy data collected at scheduled visits (e.g., eCOA, ClinRO) will be used in all analyses unless it is missing. If an assessment is missing at a scheduled visit, an unscheduled post-baseline assessment can be used provided it falls within the window interval as follows: a ±2 day window is used for Visit 3 (Week 1), Visit 4 (Week 2), and Visit 5 (Week 4); and a ±4 day window is used to Visit 6 (Week 8), Visit 7 (Week 12), and Visit 8 (Week 16). If there is more than 1 unscheduled visit within the defined visit window and no scheduled visit assessment is available, the unscheduled visit closest to the scheduled visit date will be used. If two unscheduled visits of equal distance are available, then the latter of the two will be used.

Postbaseline daily diary endpoints will be the mean of weekly visit windows (diary windows) anchored on day of first dose (Day 1) and day of Week 16 scheduled visit. Weeks 1-14 are defined as follows:

<table>
<thead>
<tr>
<th>Week</th>
<th>Days</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1-7</td>
</tr>
<tr>
<td>2</td>
<td>8-14</td>
</tr>
<tr>
<td>3</td>
<td>15-21</td>
</tr>
<tr>
<td>4</td>
<td>22-28</td>
</tr>
<tr>
<td>5</td>
<td>29-35</td>
</tr>
<tr>
<td>6</td>
<td>36-42</td>
</tr>
<tr>
<td>7</td>
<td>43-49</td>
</tr>
<tr>
<td>8</td>
<td>50-56</td>
</tr>
<tr>
<td>9</td>
<td>57-63</td>
</tr>
<tr>
<td>10</td>
<td>64-70</td>
</tr>
<tr>
<td>11</td>
<td>71-77</td>
</tr>
<tr>
<td>12</td>
<td>78-84</td>
</tr>
<tr>
<td>13</td>
<td>85-91</td>
</tr>
<tr>
<td>14</td>
<td>92-98</td>
</tr>
</tbody>
</table>
The Week 16 diary window is the 7 days prior to the scheduled Week 16 visit. If there is no Week 16 scheduled visit, the 7 days prior to the last visit (whether scheduled or unscheduled) occurring after Day 105 constitutes the Week 16 diary window if one exists. If there is no visit on which to anchor the Week 16 diary window, the Week 16 interval and its associated mean are defined as missing. If there are less than 4 non-missing assessments in the Week 16 diary window, the interval can be extended up to 7 additional days, one at a time, to obtain the most recent 4 non-missing values. The assessment of whether 4 non-missing values exist in the Week 16 diary window, and subsequent extension of that window, does not consider censored data in window construction (i.e., they are counted as non-missing unless they are truly unobserved). If the Week 16 diary window has less than 4 non-missing values after extending the Week 16 diary window up to a maximum of 14 days, the Week 16 diary window is defined as 7 days and the mean of the window is missing.

The lower bound of Week 15 diary window is defined as Day 99. The upper bound of the Week 15 diary window is the minimum of either Day 105 or the lower bound of the Week 16 diary window -1. Consequently, Week 15 may be less than 4 days if the Week 16 scheduled visit is before Day 112. Moreover, as Week 15 diary window cannot exceed 7 days, there could be daily assessments between Weeks 15 and 16 diary windows that do not fall into a diary window. If after constructing the diary windows, there are fewer than 4 non-missing values the mean for that particular window is missing and subject to imputation rules.

The postbaseline value of the actigraphy analyses will be analyzed similarly through Week 4 (Visit 5) or early discontinuation but will include time. Thus, Week 1 will be the mean of the 7 days of actigraphy events which has a start date and time occurring within 168 hours of the date and time of first study drug administration. The Week 2, Week 3 and Week 4 scores will be similarly defined. If there are less than 4 non-missing assessments occurring in at least 4 separate 24-hour increments, the weekly interval will be missing. Furthermore, as some analyses require use of the primary censoring rule, assessments collected on the day of rescue or afterwards will be excluded from the weekly visit interval calculation when implementing the rule for daily diary and actigraphy analyses. If, after exclusion of these records, there are less than 4 non-missing assessments, the weekly interval which implements the primary censoring rule will be missing. The post-study follow-up weekly score for daily diaries will be calculated as the mean of the 7 days prior to the follow-up visit which occur after last dose of study treatment.

6.2.3. Analysis Methods
The main analysis method of categorical efficacy variables and health outcomes variables will use a logistic regression analysis with region, baseline disease severity (IGA), baseline value and treatment group in the model. Firth’s correction will be used in order to accommodate (potential) sparse response rates. The p-value for the odds ratio from the logistic regression model will be used for statistical inference, unless Firth’s correction still results in quasi-separation. In that case, Fisher’s exact test will be used for statistical inference. The difference in percentages and 100(1-alpha)% CI of the difference in percentages using the Newcombe-
Wilson method without continuity correction will be reported. The p-value from the Fisher’s exact test will also be produced as a secondary analysis.

The main analysis method for all continuous efficacy and health outcomes variables will use mixed model repeated measures (MMRM) analysis. The MMRM model will use a restricted maximum likelihood (REML) estimation. The model will include treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects. For daily diary assessments, the model for analyses up to Week 16 will include all weekly assessments. An unstructured (co)variance structure will be used to model the between- and within-patient errors. If this analysis fails to converge, the heterogeneous autoregressive [ARH(1)], followed by the heterogeneous compound symmetry (CSH), followed by the heterogeneous Toeplitz (TOEPH) will be used. The Kenward-Roger method will be used to estimate the degrees of freedom. Treatment least squares means (LSM) will be estimated within the framework of the MMRM using type 3 sums of squares. Differences in LSM between each dose of BARI and placebo (and associated p-values, standard errors and 95% CI) will be used for statistical inference. The LSM difference, standard error, p-value and 95% CI will be reported.

Treatment comparisons for continuous efficacy and health outcomes variables may also be made using analysis of covariance (ANCOVA) for primary and key secondary objectives. When an ANCOVA model is used, the model includes region, baseline disease severity, treatment group, and baseline value. Treatment LSM will be estimated within the framework of the ANCOVA using type 3 sums of squares. Reported differences in LSM and associated p-values, standard errors and 95% CI will be used for statistical inference. Treatment-by-region interaction will also be added to the model for sensitivity purposes and is discussed in Section 6.5.

Beginning on Day 14 a Cox proportional hazard (CPH) model of time (in days) to first observance of a 4-point itch reduction with effects for treatment, region, baseline mean itch, and disease severity will be used to test for treatment differences from placebo. For this analysis, daily itch scores will be compared to the baseline to determine if a 4-point itch reduction has been achieved in patients with a baseline itch of at least 4. The baseline for itch NRS is defined in Section 6.2.2. The day on which the first 4-point reduction in itch NRS is achieved will be modeled. If any significant treatment difference is observed then the same analysis will be performed on Day 13. This process of evaluating at the next lowest day will proceed until no significant differences are observed. No adjustments for multiple tests and multiple comparisons will be used. This analysis uses the Primary Censoring Rule for patients who are rescued or permanently discontinue study drug (see Section 6.4). Missing daily itch data will be replaced using NRI rule which means missing data is replaced with a non-response which would entail replacing missing values with a time to event of > 14 days, censored; >13 days, censored, etc., depending on the window being used. If the model assumptions for the CPH model do not hold, a log-rank test will be used.

Restricted mean survival time will be evaluated at Days 2, 3, 4 and 5 as an exploratory analysis. The model will include terms for baseline disease severity (IGA), baseline itch, region, and treatment group.
Fisher’s exact test will be used to test for differences between each baricitinib dose and placebo in proportions of patients experiencing adverse events (AEs), discontinuation from study drug, and for other categorical safety data. Continuous vital signs, body weight, and other continuous safety variables, including laboratory variables will be analyzed by an ANCOVA with treatment group and baseline value in the model. The significance of within-treatment group changes from baseline will be evaluated by testing whether or not the treatment group LSM changes from baseline are different from zero; the standard error for the LSM change will also be displayed. Differences in LSM will be displayed, with the p-value associated with the LSM comparison to placebo and a 95% CI on the LSM difference also provided. In addition to the LSMS for each group, the within-group p-value for the change from baseline will be displayed.

6.2.4. Derived Data

- Age (year), derived using first dose date as the reference start date and July 1st of birth year and truncated to a whole-year (integer) age. Patients whose derived age is less than 18 will have the required minimum age of 18 at informed confirmed; reporting for age, age groups, and lab ranges, however will be based on their derived age.
- Age group (<65, ≥65 years old)
- Age group (<65, ≥65 to <75, ≥75 to <85, ≥85 years old)
- Body Mass Index (BMI) (kg/m$^2$) = Weight (kg)/((Height (cm)/100)$^2$)
- BMI category (<25 kg/m$^2$, ≥25 to <30 kg/m$^2$, ≥30 kg/m$^2$)
- The duration of AD from diagnosis (years) = [(Date of informed consent – Date of AD diagnosis )+1]/ 365.25.
  - If year of onset is missing, duration of AD will be set as missing. Otherwise, unknown month will be taken as January, and unknown day will be taken as 01. The duration of AD will be rounded to 1 decimal place.
- Duration of AD (years) category (0 to <2 years, 2 to < 5 years, 5 to <10 years, 10 to <20 years, ≥20 years)
- Diagnosis age (years), derived using diagnosis date as the reference start date and July 1st of birth year and truncated to a whole-integer age.
- Diagnosis age group (<18, ≥18 to <50, ≥50 years old)
- Change from baseline = postbaseline measurement at Visit x – baseline measurement.
  - If a baseline value is missing, it will not be imputed and the change from baseline will not be calculated.
- Percent change from baseline at Visit x: ((Post-baseline measurement at Visit x - Baseline measurement)/Baseline measurement)*100.
  - If a baseline value is missing, it will not be imputed and percent change from baseline will not be calculated.
- Weight (kg) = weight (lbs) * 0.454.
- Weight category (<60 kg, ≥60 to <100 kg, ≥100 kg)
- Height (cm) = height (in) * 2.54.
- Cyclosporine inadequate efficacy (yes, no)
  - Set yes if the reason for discontinuation is inadequate response.
• Cyclosporine intolerance (yes, no)
  o Set yes if the reasons for discontinuation are: intolerance to medication or contraindication (Physician indicated cyclosporine was used and a contraindication was noted).
• Cyclosporine contraindication [ineligible] (yes, no)
  o Set to yes if cyclosporine never used because of a contraindication
• Cyclosporine inadvisable (yes, no)
  • Set to yes if the following reasons were selected for either not using the medication or discontinuing the medication:
    o Reason for not using medication: Physician decision, concern about side effects, unfavorable benefit risk, contraindication.
    o Reasons for discontinuation: inadequate response, intolerance to medication, or contraindication.
• TCNI inadequate efficacy (yes, no)
  o Set yes if the reason for discontinuation is inadequate response.
• TCNI intolerance (yes, no)
  o Set yes if the reasons for discontinuation are: intolerance to medication or contraindication (Physician indicated TCNI was used and a contraindication was noted).
• TCNI contraindication / [ineligible](yes, no)
  o Set to yes if TCNI never used because of a contraindication
• TCNI inadvisable (yes, no)
  • Set to yes if the following reasons were selected for either not using the medication or discontinuing the medication:
    o Reason for not using medication: Physician decision, concern about side effects, unfavorable benefit risk, contraindication.
    o Reasons for discontinuation: inadequate response, intolerance to medication, or contraindication.

6.3. Covariate Adjustment
The randomization to treatment groups at Week 0 (Visit 2) is stratified by disease severity (IGA) and geographic region as described in Section 5.1. Unless otherwise specified, the statistical analysis models will adjust for these stratification variables. The covariates used in the logistic model for categorical data will include the parameter value at baseline. The covariates used in the ANCOVA model for continuous data will include the parameter value at baseline. Inclusion of baseline in the model ensures treatment LSM are estimated at the same baseline value. When an MMRM analysis is performed, baseline value and baseline-by-visit interactions will be included as covariates.

6.4. Handling of Dropouts or Missing Data
Intercurrent events (ICH E9 R1) are events which occur after the treatment initiation and make it impossible to measure a variable or influence how it would be interpreted.
Depending on the estimand being addressed, different methods will be used to handle missing data as a result of intercurrent events. Intercurrent events can occur through the following:

- application of one of the censoring rules (including after permanent study drug discontinuation or after rescue therapy)
- discontinuation
- missing an intermediate visit prior to discontinuation or rescue
- lost to follow-up.

Non-censor intercurrent events are events that are not due to the application of any censoring rule, i.e., the last 3 items in the list above.

Note that as efficacy and health outcome data can accrue after a patient permanently discontinues study drug or begins rescue therapy, specific general censoring rules to the data will be applied to all efficacy and health outcome observations subsequent to these events depending on the estimand being addressed. These specific censoring rules are described below.

The *primary censoring rule* will censor efficacy and health outcome data after permanent study drug discontinuation or after rescue therapy. This censoring rule will be applied to all continuous and categorical efficacy and health outcome endpoints. This censoring rule is equivalent to using all the data up to rescue.

A *secondary censoring rule* will only censor efficacy and health outcome data after permanent study drug discontinuation. This sensitivity analysis will include all observed values up to study drug discontinuation. The secondary censoring rule will be applied to primary and key secondary efficacy and health outcome endpoints as sensitivity analyses.

Table JAHL.6.1 describes the planned imputation methods for efficacy and health outcome endpoints with associated censoring rules. Sections 6.4.1 through 6.4.5 summarize the methodology of each imputation rule.

**Table JAHL.6.1. Imputation Techniques for Various Variables**

<table>
<thead>
<tr>
<th>Efficacy and Health Outcome Endpoints</th>
<th>Imputation Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>IGA(0,1), EASI75, 4-point Itch NRS improvement, EASI90, SCORAD75</td>
<td>NRI(a), pMI(a), Tipping point(a)</td>
</tr>
<tr>
<td>EASI percent change, ADSS Item 2 change, Skin Pain NRS change</td>
<td>MMRM(a), mLOCF(a), pMI(a)</td>
</tr>
<tr>
<td>All remaining categorical measures</td>
<td>NRI(a)</td>
</tr>
<tr>
<td>All remaining continuous efficacy and health outcome measures</td>
<td>MMRM(a), mLOCF(a)</td>
</tr>
</tbody>
</table>
Abbreviations: ADSS = Atopic Dermatitis Sleep Scale; EASI = Eczema Area and Severity Index score; IGA = Investigator’s Global Assessment for AD; mLOCF = modified last observation carried forward; MMRM = mixed model repeated measures; NRI = nonresponder imputation, NRS = Numeric Rating Scale; pMI = placebo multiple imputation; SCORAD = SCORing Atopic Dermatitis.

a Analyses utilizing the primary censoring rule.
b Analyses utilizing the secondary censoring rule.

6.4.1. Nonresponder Imputation

A nonresponder imputation (NRI) method imputes missing values as non-responses and can be justified based on the composite strategy for handling intercurrent events (ICH E9 R1). This imputation procedure assumes the effects of treatments disappear after the occurrence of an intercurrent event defined by the associated censoring rule.

All categorical endpoints will utilize the NRI method after applying the primary censoring rule to patients who permanently discontinued study drug or were rescued (described in Section 6.4). Additionally, all primary and key secondary categorical endpoints will utilize NRI after applying the secondary censoring rule as sensitivity analyses. For analyses which utilize either of the censoring methods, randomized patients without at least 1 post-baseline observation will be defined as nonresponders for all visits.

6.4.2. Mixed Model for Repeated Measures

Mixed Model for Repeated Measures analyses will be performed on continuous endpoints to mitigate the impact of missing data. This approach assumes missing observations are missing-at-random (missingness is related to observed data) and borrows information from patients in the same treatment arm taking into account both the missingness of data through the correlation of the repeated measurements.

Essentially MMRM estimates the treatment effects had all patients remained on their initial treatment throughout the study. For this reason, the MMRM imputation implies a different estimand (hypothetical strategy [ICH E9 R1]) than the one used for NRI on categorical outcomes.

All continuous endpoints will utilize MMRM after applying the primary censoring rule. As sensitivity analyses, all secondary continuous endpoints will also utilize MMRM after applying the secondary censoring rule (Table JAHL.6.1).

6.4.3. Modified Last Observation Carried Forward

For continuous measure, a modified last observation carried forward (mLOCF) imputation technique replaces missing data with the most recent non-missing post-baseline assessment. The specific modification to the LOCF is data after an intercurrent event will not be carried forward thus the mLOCF is applied after the specified censoring rule is implemented. The mLOCF assumes the effect of treatment remain the same after the event that caused missing data as it was just prior to the missing data event. Analyses using mLOCF require a nonmissing baseline and at least 1 postbaseline measure otherwise the data is missing for analyses purposes. Analyses using mLOCF help ensure the number of randomized patients who were assessed post-baseline
is maximized and is reasonable for this data as data directly prior to an intercurrent event (such as initiation of rescue therapy or drop out) is likely a non- efficacious response.

All continuous efficacy and health outcomes endpoints will use with mLOCF imputation methodology with an ANCOVA as sensitivity analyses to the MMRM analyses.

6.4.4. Placebo Multiple Imputation

The Placebo Multiple Imputation (pMI) methodology will be used as a sensitivity analysis for the analysis of the primary efficacy endpoint (IGA 0 or 1 at Week 16) as well as the key secondary endpoints at Week 16. In these sensitivity analyses the primary censoring rule will be applied.

The pMI assumes that the statistical behavior of drug- and placebo- treated patients after the occurrence of intercurrent events will be the same as if patients were treated with placebo. Thus, in the effectiveness context, pMI assumes no pharmacological benefit of the drug after the occurrence of intercurrent events but is a more conservative approach than mLOCF because it accounts for uncertainty of imputation, and therefore does not underestimate standard errors, and it limits bias. In the efficacy context pMI is a specific form of a missing not at random analysis and expected to yield a conservative estimate of efficacy.

In the pMI analysis, multiple imputations are used to replace missing outcomes for drug- and placebo-treated patients who have an intercurrent event using multiple draws from the posterior predictive distribution estimated from the placebo arm. The binary outcomes will then be derived from the imputed data.

Data are processed sequentially by repeatedly calling SAS® PROC MI to impute missing outcomes at visits $t=1,\ldots, T$.

1. Initialization: Set $t=0$ (baseline visit)

2. Iteration: Set $t=t+1$. Create a data set combining records from drug- and placebo-treated patients with columns for covariates $X$ and outcomes at visits 1,$\ldots,t$ with outcomes for all drug-treated patients set to missing at visit $t$ and set to observed or imputed values at visits 1,$\ldots,t-1$.

3. Imputation: Run Bayesian regression in SAS® PROC MI on this data to impute missing values for visit $t$ using previous outcomes for visits 1 to $t-1$ and baseline covariates. Note that only placebo data will be used to estimate the imputation model since no outcome is available for drug-treated patients at visit $t$.

4. Replace imputed data for all drug-treated patients at visit $t$ with their observed values, whenever available up to permanent study drug discontinuation and/or rescue (if censoring on rescue). If $t < T$ then go to Step 2, otherwise proceed to Step 5.

5. Repeat steps 1-4, $m$ times with different seed values to create $m$ imputed complete data sets.

Analysis: For continuous endpoints, fit its treatment response model (MMRM) for each completed data set. For the primary and secondary key efficacy endpoints [IGA (0,1), EASI75,
EASI90, SCORAD75, and 4-point improvement from baseline in Itch NRS], the binary outcomes will be derived from the imputed data for each patient before fitting the logistic regression model.

The number of imputed data sets will be \( m=100 \) and a 6-digit seed value will be pre-specified for each analysis. Within the program, the seed will be used to generate the \( m \) seeds needed for imputation. The initial seed values are given in Table JAHL.6.2.

### Table JAHL.6.2. Seed Values for Multiple Imputation

<table>
<thead>
<tr>
<th>Analysis</th>
<th>Seed value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proportion of patients achieving IGA of 0 or 1 with a ≥2-point improvement from baseline at Week 16 using the primary censoring rule</td>
<td>123450</td>
</tr>
<tr>
<td>Percent change from baseline in EASI score at 16 weeks using the primary censoring rule. EASI75 and EASI90 will leverage imputation from EASI and therefore do not need a new seed number.</td>
<td>123451</td>
</tr>
<tr>
<td>Proportion of patients achieving SCORAD75 at 16 week using the primary censoring rule, with data up to rescue</td>
<td>123452</td>
</tr>
<tr>
<td>Proportions of patients achieving a 4-point improvement from baseline in Itch NRS at Week 16 using the primary censoring rule</td>
<td>123453</td>
</tr>
<tr>
<td>Mean change from baseline in Skin Pain NRS at Week 16 using the primary censoring rule</td>
<td>123454</td>
</tr>
<tr>
<td>Mean change from baseline in the score of Item 2 of the ADSS at Week 16 using the primary censoring rule</td>
<td>123455</td>
</tr>
</tbody>
</table>

Abbreviations: ADSS = Atopic Dermatitis Sleep Scale; EASI = Eczema Area and Severity Index score; IGA = Investigator’s Global Assessment for AD; NRS = Numeric Rating Scale; SCORAD = SCORing Atopic Dermatitis.

The final inference on treatment difference is conducted from the multiple datasets using Rubin’s combining rules, as implemented in SAS® PROC MIANALYZE.

### 6.4.5. Tipping Point Analyses

To investigate the missing data mechanism, sensitivity analyses using multiple imputation (MI) under the missing not at random assumption will be provided for the following primary and key secondary objectives:

- IGA (0,1) with ≥2-point improvement at Week 16, baricitinib 1-mg, 2-mg and 4-mg compared to placebo
- EASI percent change from baseline to Week 16, baricitinib 1-mg, 2-mg and 4-mg compared to placebo
- Itch NRS 4-point improvement from baseline to Week 16, baricitinib 1-mg, 2-mg and 4-mg compared to placebo

All patients in the ITT population will be included. Data after the occurrence of intercurrent events (after application of the primary censoring rule) will be set to missing.

Within each analysis, a most extreme case will be considered, in which all missing data for patients randomized to baricitinib 1-mg, 2-mg or 4-mg will be imputed using the worst possible
result and all missing data for patients randomized to placebo will be imputed with the best possible result. Treatment differences will be analyzed using logistic regression or ANCOVA (Section 6.1) as appropriate.

For continuous variables, the following process will be used to determine the tipping point:

1. To handle intermittent missing visit data, a Markov chain Monte Carlo method (SAS® Proc MI with MCMC option) will be used to create a monotone missing pattern.
2. A set of Bayesian regressions (using SAS® Proc MI with MONOTONE option) will be used for the imputation of monotone dropouts. Starting from the first visit with at least 1 missing value, the regression models will be fit sequentially with treatment as a fixed effect and values from the previous visits as covariates.
3. A delta score is added to all imputed scores at the primary time point for patients in the baricitinib treatment groups, thus worsening the imputed value. The delta score is capped for patients based on the range of the outcome measure being analyzed.
4. Treatment differences between baricitinib and placebo are analyzed for each imputed dataset using ANCOVA (Section 6.1). Results across the imputed datasets are aggregated using SAS® Proc MIANALYZE in order to compute a p-value for the treatment comparisons for the given delta value.
5. Steps 3 and 4 are repeated, and the delta value added to the imputed baricitinib scores is gradually increased. The tipping point is identified as the delta value which leads to a loss of statistical significance (aggregated p-value >0.05) when evaluating baricitinib relative to the placebo group.

As a reference, for each delta value used in Steps 3 through 5, a fixed selection of delta values (ranging from slightly negative to slightly positive) will be added to imputed values in the placebo group, and Step 4 will be performed for the combination. This will result in a 2-d table, with the columns representing the delta values added to the imputed placebo responses, and the rows representing the delta values added to the imputed baricitinib responses. Separate 2-d tables will compare each baricitinib dose group to placebo.

A similar process will be used for the categorical variables:

1. Missing responses in the baricitinib groups will be imputed with a range of low response probabilities, including probabilities of 0, 0.1, and 0.2.
2. For missing responses in the placebo group, a range of responses probabilities (for example, probability = 0, 0.2 … 1) will be used to impute the missing values. Multiple imputed datasets will be generated for each response probability.
3. Treatment differences between baricitinib and placebo are analyzed for each imputed dataset using logistic regression (Section 6.1). Results across the imputed datasets are aggregated using SAS® Proc MIANALYZE in order to compute a p-value for the treatment comparisons for the given response probability. If the probability values do not
allow for any variation between the multiple imputed datasets (for example, all missing responses in the placebo and baricitinib groups are imputed as responders and nonresponders, respectively), then the p-value from the single imputed dataset will be used.

The tipping point is identified as the response probability value within the placebo group that leads to a loss of statistical significance when evaluating baricitinib relative to placebo.

For tipping point analyses the number of imputed data sets will be $m=100$ and the seed values to start the pseudorandom number generator of SAS Proc MI (same values for MCMC option and for MONOTONE option) are given in Table JAHL.6.3.

Table JAHL.6.3. Seed Values for Imputation

<table>
<thead>
<tr>
<th>Analysis</th>
<th>Seed value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proportion of patients achieving IGA (0,1) with ≥2-point improvement at Week 16; primary censoring rule</td>
<td>123470</td>
</tr>
<tr>
<td>Proportion of patients achieving EASI75 at Week 16; primary censoring rule</td>
<td>123471</td>
</tr>
<tr>
<td>Proportion of patients achieving EASI90 at Week 16; primary censoring rule</td>
<td>123472</td>
</tr>
<tr>
<td>Proportions of patients achieving a 4-point improvement from baseline in Itch NRS at Week 16, primary censoring rule</td>
<td>123473</td>
</tr>
<tr>
<td>Proportion of patients achieving SCORAD75 at Week 16; primary censoring rule</td>
<td>123473</td>
</tr>
</tbody>
</table>

6.5. Multicenter Studies

This study will be conducted by multiple investigators at multiple sites internationally. The countries will be categorized into geographic regions, as described in Section 5.2.

For the analysis of the primary endpoint, treatment-by-region interaction will be added to the logistic regression model as a sensitivity analysis and results from this model will be compared to the primary model (without the interaction effect). If the treatment-by-region interaction is significant at a 2-sided $\alpha$ level of 0.1, the nature of this interaction will be inspected as to whether it is quantitative (i.e., the treatment effect is consistent in direction across all regions but not in size of treatment effect) or qualitative (the treatment is beneficial in some but not all regions). If the treatment-by-region interaction effect is found to be quantitative, results from the primary model will be presented. If the treatment-by-region interaction effect is found to be qualitative, further inspection will be used to identify in which regions baricitinib is found to be more beneficial.

6.6. Multiple Comparisons/Multiplicity

The primary and key secondary endpoints will be adjusted for multiplicity in order to control the overall family-wise Type I error rate at a 2-sided alpha level of 0.05.

The following is a list of primary and key secondary endpoints to be tested. The subscript for $H$ denotes dose (4-mg, 2-mg, 1-mg), the numerical identifier of the endpoint within the dose, and the type of hypothesis (0 for null, 1 for alternative), respectively.
Primary Null Hypotheses:

- H_{4,1,0}: Proportion of baricitinib 4-mg patients achieving IGA of 0 or 1 with a ≥2-point improvement from baseline at Week 16 is less than or equal to the proportion of placebo patients achieving IGA of 0 or 1 with a ≥2-point improvement from baseline at Week 16 [IGA0-1]
- H_{2,1,0}: Proportion of baricitinib 2-mg patients achieving IGA of 0 or 1 with a ≥2-point improvement from baseline at Week 16 is less than or equal to the proportion of placebo patients achieving IGA of 0 or 1 with a ≥2-point improvement from baseline at Week 16 [IGA0-1]

Key Secondary Null Hypotheses:

- H_{4,2,0}: Proportion of baricitinib 4-mg patients achieving EASI75 is less than or equal to the proportion of placebo patients achieving EASI75 at Week 16 [EASI75]
- H_{4,3,0}: Proportion of baricitinib 4-mg patients achieving a 4-point improvement in Itch NRS is less than or equal to the proportion of placebo patients achieving a 4-point improvement in Itch NRS at Week 16 [ITCH W16]
- H_{4,4,0}: Percent change from baseline in EASI score for baricitinib 4-mg patients is greater than or equal to the percent change from baseline in EASI score for placebo patients at Week 16 [EASI PCFB]
- H_{4,5,0}: Proportion of baricitinib 4-mg patients achieving a 4-point improvement in Itch NRS is less than or equal to the proportion of placebo patients achieving a 4-point improvement in Itch NRS at Week 4 [ITCH W4]
- H_{4,6,0}: Proportion of baricitinib 4-mg patients achieving SCORAD75 is less than or equal to the proportion of placebo patients achieving SCORAD75 at Week 16 [SCORAD75]
- H_{4,7,0}: Proportion of baricitinib 4-mg patients achieving EASI90 is less than or equal to the proportion of placebo patients achieving EASI90 at Week 16 [EASI 90]
- H_{4,8,0}: Mean change from baseline in Skin Pain NRS for baricitinib 4-mg patients is greater than or equal to the mean change from baseline in Skin Pain NRS for placebo patients at Week 16 [PAIN W16]
- H_{4,9,0}: Mean change from baseline in the score of Item 2 of the ADSS for baricitinib 4-mg patients is greater than or equal to the mean change from baseline in the score of Item 2 of the ADSS for placebo patients at Week 16 [ADSS2 W16]
- H_{4,10,0}: Proportion of baricitinib 4-mg patients achieving a 4-point improvement in Itch NRS is less than or equal to the proportion of placebo patients achieving a 4-point improvement in Itch NRS at Week 2 [ITCH W2]
- H_{4,11,0}: Mean change from baseline in the score of Item 2 of the ADSS for baricitinib 4-mg patients is greater than or equal to the mean change from baseline in the score of Item 2 of the ADSS for placebo patients at Week 1 [ADSS2 W1]
- H_{4,12,0}: Proportion of baricitinib 4-mg patients achieving a 4-point improvement in Itch NRS is less than or equal to the proportion of placebo patients achieving a 4-point improvement in Itch NRS at Week 1 [ITCH W1]
- H_{3,2,0}: Proportion of baricitinib 2-mg patients achieving EASI75 is less than or equal to the proportion of placebo patients achieving EASI75 at Week 16 [EASI75]
- **H2,3,0**: Proportion of baricitinib 2-mg patients achieving a 4-point improvement in Itch NRS is less than or equal to the proportion of placebo patients achieving a 4-point improvement in Itch NRS at Week 16 [ITCH W16]

- **H2,4,0**: Percent change from baseline in EASI score for baricitinib 2-mg patients is greater than or equal to the percent change from baseline in EASI score for placebo patients at Week 16 [EASI PCFB]

- **H2,5,0**: Proportion of baricitinib 2-mg patients achieving a 4-point improvement in Itch NRS is less than or equal to the proportion of placebo patients achieving a 4-point improvement in Itch NRS at Week 4 [ITCH W4]

- **H2,6,0**: Proportion of baricitinib 2-mg patients achieving SCORAD75 is less than or equal to the proportion of placebo patients achieving SCORAD75 at Week 16 [SCORAD75]

- **H2,7,0**: Proportion of baricitinib 2-mg patients achieving EASI90 is less than or equal to the proportion of placebo patients achieving EASI90 at Week 16 [EASI90]

- **H2,8,0**: Mean change from baseline in Skin Pain NRS for baricitinib 2-mg patients is greater than or equal to the mean change from baseline in Skin Pain NRS for placebo patients at Week 16 [PAIN W16]

- **H2,9,0**: Mean change from baseline in the score of Item 2 of the ADSS for baricitinib 2-mg patients is greater than or equal to the mean change from baseline in the score of Item 2 of the ADSS for placebo patients at Week 16 [ADSS2 W16]

- **H2,10,0**: Proportion of baricitinib 2-mg patients achieving a 4-point improvement in Itch NRS is less than or equal to the proportion of placebo patients achieving a 4-point improvement in Itch NRS at Week 2 [ITCH W2]

- **H2,11,0**: Mean change from baseline in the score of Item 2 of the ADSS for baricitinib 2-mg patients is greater than or equal to the mean change from baseline in the score of Item 2 of the ADSS for placebo patients at Week 1 [ADSS2 W1]

- **H2,12,0**: Proportion of baricitinib 2-mg patients achieving a 4-point improvement in Itch NRS is less than or equal to the proportion of placebo patients achieving a 4-point improvement in Itch NRS at Week 1 [ITCH W1]

- **H1,1,0**: Proportion of baricitinib 1-mg patients achieving IGA of 0 or 1 with a ≥2-point improvement from baseline at Week 16 is less than or equal to the proportion of placebo patients achieving IGA of 0 or 1 with a ≥2-point improvement from baseline at Week 16 [IGA0-1]

- **H1,2,0**: Proportion of baricitinib 1-mg patients achieving EASI75 is less than or equal to the proportion of placebo patients achieving EASI75 at Week 16 [EASI75]

- **H1,3,0**: Proportion of baricitinib 1-mg patients achieving a 4-point improvement in Itch NRS is less than or equal to the proportion of placebo patients achieving a 4-point improvement in Itch NRS at Week 16 [ITCH W16]

- **H1,4,0**: Percent change from baseline in EASI score for baricitinib 1-mg patients is greater than or equal to the percent change from baseline in EASI score for placebo patients at Week 16 [EASI PCFB]

- **H1,5,0**: Proportion of baricitinib 1-mg patients achieving a 4-point improvement in Itch NRS is less than or equal to the proportion of placebo patients achieving a 4-point improvement in Itch NRS at Week 4 [ITCH W4]

- **H1,6,0**: Proportion of baricitinib 1-mg patients achieving SCORAD75 is less than or equal to the proportion of placebo patients achieving SCORAD75 at Week 16 [SCORAD75]
• **H_{1,7,0}:** Proportion of baricitinib 1-mg patients achieving EASI90 is less than or equal to the proportion of placebo patients achieving EASI90 at Week 16 [EASI90]

• **H_{1,8,0}:** Mean change from baseline in Skin Pain NRS for baricitinib 1-mg patients is greater than or equal to the mean change from baseline in Skin Pain NRS for placebo patients at Week 16 [PAIN W16]

• **H_{1,9,0}:** Mean change from baseline in the score of Item 2 of the ADSS for baricitinib 1-mg patients is greater than or equal to the mean change from baseline in the score of Item 2 of the ADSS for placebo patients at Week 16 [ADSS2 W16]

• **H_{1,10,0}:** Proportion of baricitinib 1-mg patients achieving a 4-point improvement in Itch NRS is less than or equal to the proportion of placebo patients achieving a 4-point improvement in Itch NRS at Week 2 [ITCH W2]

• **H_{1,11,0}:** Mean change from baseline in the score of Item 2 of the ADSS for baricitinib 1-mg patients is greater than or equal to the mean change from baseline in the score of Item 2 of the ADSS for placebo patients at Week 1 [ADSS2 W1]

• **H_{1,12,0}:** Proportion of baricitinib 1-mg patients achieving a 4-point improvement in Itch NRS is less than or equal to the proportion of placebo patients achieving a 4-point improvement in Itch NRS at Week 1 [ITCH W1]

The multiple testing procedure is specified by Figure JAHL.6.1.
The primary null hypotheses includes testing whether neither of baricitinib 4-mg and baricitinib 2-mg dose is superior to placebo at the primary endpoint defined as the proportion of placebo patients achieving IGA of 0 or 1 and ≥2 point improvement from baseline at Week 16. The initial alpha allocation is split evenly across these hypothesis to give them “equal footing”, i.e., $H_{4,1,0}$ and $H_{2,1,0}$ will each be first tested at a 2-sided alpha level of 0.025. Together with these primary hypotheses, multiplicity adjusted analyses will be performed on key secondary null hypotheses to control the overall family wise Type I error rate at a 2-sided alpha level of 0.05.
The graphical multiple testing procedure described in Bretz et al. (2011), which is a closed testing procedure will be used; hence it strongly controls the family-wise error rate across all endpoints (Alosh et al. 2014).

If $H_{4,1,0}$ and $H_{2,1,0}$ are not rejected, no further testing is conducted as the $\alpha_0$ for that test is considered “spent” and cannot be passed to other endpoints. If $H_{4,1,0}$ or $H_{2,1,0}$ is rejected, the testing procedure continues in either branches (starting with $H_{4,2,0}$ and $H_{2,2,0}$ respectively), with $\alpha$ propagated according to the directed edges and propagation weights displayed in Figure JAHL.6.1. Each time a hypothesis is rejected, the graph is updated to reflect the reallocation of $\alpha$, which is considered “recycled” by Alosh et al. (2014). This iterative process of updating the graph and reallocating $\alpha$ is repeated until all hypotheses have been tested or when no remaining hypotheses can be rejected at their corresponding $\alpha$ levels.

For Japan, the same testing strategy described in the Figure JAHL.6.1 will be used, however, the proportion of patients achieving EASI75 and IGA of 0 or 1 at Week 16 are considered co-primary. Both endpoints have to meet statistical significance compared with placebo with a specific $\alpha$ level based on the graphical multiple testing procedure in order to demonstrate a superiority of a given baricitinib dose (baricitinib 4-mg and/or baricitinib 2-mg) compared with placebo. That is, $H_{4,1,0}$ and $H_{4,2,0}$ have to be rejected in order to demonstrate the superiority of baricitinib 4-mg compared with placebo and $H_{2,1,0}$ and $H_{2,2,0}$ have to be rejected in order to demonstrate the superiority of baricitinib 2-mg compared with placebo.

There will be no adjustment for multiple comparisons for any other analyses.

### 6.7. Patient Disposition

An overview of patient populations will be summarized by treatment group. Frequency counts and percentages of patients excluded prior to randomization by primary reason for exclusion will be provided for patients who failed to meet study entry requirements during screening.

Patient disposition through Week 16 will be summarized using the ITT population. Frequency counts and percentages of patients who complete the study treatment visits or discontinue early from the study along with whether they completed follow-up, did not complete follow-up or enrolled into the extension will be summarized separately by treatment group for patients who are not rescued and for patients who are rescued, along with their reason for study discontinuation. Frequency counts and percentages of patients who complete the treatment or discontinue treatment early will also be summarized separately by treatment group for patients who are not rescued and for patients who are rescued, along with their reason for treatment discontinuation.

A listing of patient disposition will be provided for all randomized patients, with the extent of their participation in the study and the reason for discontinuation. A listing of all randomized patients with their treatment assignment will also be provided.
6.8. Patient Characteristics
Patient characteristics including demographics and baseline characteristics will be summarized descriptively by treatment group for the ITT population. Historical illnesses and pre-existing conditions will be summarized descriptively by treatment group for the ITT population. No formal statistical comparisons will be made among treatment groups unless otherwise stated.

6.8.1. Demographics
Patient demographics will be summarized as described above. The following demographic information will be included:

- Age
- Age group (<65 vs. ≥65)
- Age group (<65, ≥65 to <75, ≥75 to <85, ≥85)
- Gender (male, female)
- Race (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other Pacific Islander, White, Multiple)
- Region (as defined in Table JAHL.5.1)
- Country
- Weight (kg)
- Weight category (<60 kg, ≥60 to <100 kg, ≥100 kg)
- Height (cm)
- BMI (kg/m²)
- BMI category (<25 kg/m², ≥25 to <30 kg/m², ≥30 kg/m²)

A listing of patient demographics will also be provided for the ITT population.

6.8.2. Baseline Disease Characteristics
The following baseline disease information will be categorized and presented for baseline AD clinical characteristics, baseline health outcome measures, and other baseline demographic and disease characteristics as described above:

- Duration since AD diagnosis (years)
- Duration since AD diagnosis category (0 to <2 years, 2 to <5 years, 5 to <10 years, 10 to <20 years, ≥20 years)
- Age at Diagnosis (years)
- Age Group at Diagnosis (<18 years, ≥18 to <50 years, ≥50 years)
- Habits (Alcohol: Never, Current, Former; Tobacco: Never, Current, Former)
- Skin Infections treated with a pharmacological agent within past year (yes, no, unknown; number if yes)
- Atopic Dermatitis Flares within past year (yes, no, unknown; number if yes)
- Validated Investigator’s Global Assessment for AD (IGA) score
- Eczema Area and Severity Index (EASI) score
- SCORing Atopic Dermatitis (SCORAD)
- Body Surface Area (BSA) affected by AD
- Hospital Anxiety Depression Scale (HADS) subscales
- Patient-Oriented Eczema Measure (POEM)
- Itch Numerical Rating Scale (NRS)
- Atopic Dermatitis Sleep Scale (ADSS) Item 2
- Dermatology Life Quality Index (DLQI)
- Skin Pain NRS
- Patient Global Impression of Severity (PGI-S-AD)
- Prior therapy (topical therapy only; systemic therapy)
- Prior use of Cyclosporine (yes, no)
- Cyclosporine inadequate response (yes, no)
- Cyclosporine intolerance (yes, no)
- Cyclosporine contraindication [ineligible] (yes, no)
- Cyclosporine inadvisable (yes no)
- Prior use of TCNI (yes, no)
- TCNI inadequate response (yes, no)
- TCNI intolerance (yes, no)
- TCNI contraindication [ineligible] (yes, no)
- TCNI inadvisable (yes, no)
- Vaccine (yes, no)
- Baseline renal function status: impaired (eGFR < 60 mL/min/1.73 m²) or not impaired (eGFR ≥ 60 mL/min/1.73 m²)
- Immunoglobulin E (IgE): intrinsic(<200 kU/I) or extrinsic (≥200 kU/I)

6.8.3. Historical Illness and Pre-existing Conditions

Historical illnesses are defined as those conditions recorded in the Pre-existing Conditions and Medical History electronic case report form (eCRF) or from the Prespecified Medical History: Comorbidities eCRF with an end date prior to the informed consent date. The number and percentage of patients with selected historical diagnoses will be summarized by treatment group using the ITT population. Historical diagnoses will be categorized using the Medical Dictionary for Regulatory Activities (MedDRA®, most current available version) algorithmic standardized MedDRA queries (SMQs) or similar pre-defined lists of preferred terms (PTs) of interest.

Pre-existing conditions are defined as those conditions with a start date prior to the first dose of the study drug and stop dates that are at or after the informed consent date or have no stop date (i.e., are ongoing). For events occurring on the day of the first dose of study treatment, the date and time of the onset of the event will both be used to determine if the event was pre-existing. Conditions with a partial or missing start date (or time if needed) will be assumed to be ‘not pre-existing’ unless there is evidence, through comparison of partial dates, to suggest otherwise. Pre-existing conditions will be categorized using the MedDRA SMQs or similar pre-defined lists of PTs of interest. Frequency counts and percentages of patients with selected pre-existing conditions will be summarized by treatment group using the ITT population.

6.9. Treatment Compliance

Patient compliance with study medication will be assessed from Week 0 (Visit 2) to Week 16 (Visit 8) or Early Termination using the ITT population.
All patients are expected to take 3 tablets daily from a blister pack as described in the protocol. Each blister pack contains 27 tablets. A patient is considered noncompliant if he or she misses >20% of the prescribed doses during the study, unless the patient’s study drug is withheld by the investigator. For patients who had their treatment temporarily interrupted by the investigator, the period of time that dose was withheld will be taken into account in the compliance calculation.

Compliance in the period of interest up to Visit \( x \) will be calculated as follows:

\[
\text{Compliance} = \frac{\text{total number of tablets dispensed} - \text{total number of tablets returned}}{\text{expected number of total tablets}}
\]

where

- Total number of tablets dispensed: sum of tablets dispensed in the period of interest prior to Visit \( x \);
- Total number of tablets returned: sum of the tablets returned in the period of interest prior to and including Visit \( x \);
- Expected number of tablets: number of days in the period of interest*number of tablets taken per day = \([\text{date of last dose} - \text{date of first dose} + 1] - \text{number of days of temporary drug interruption}\)*number of tablets taken per day

Patients who are significantly noncompliant (compliance <80%) through Week 16 will be excluded from the PPS population.

Descriptive statistics for percent compliance and non-compliance rate will be summarized for the ITT population by treatment group for Week 0 through Week 16. Sub-intervals of interest, such as compliance between visits, may also be presented. The number of expected doses, tablets dispensed, tablets returned, and percent compliance will be listed by patient for Week 0 through Week 16.

### 6.9.1. Rescue Treatment

Descriptive statistics for drug accountability of topical low and moderate potency rescue medication provided by the sponsor will also be supplied, including the amount utilized throughout the treatment period. The total amount in grams for low and moderate potency will be summarized between scheduled visits as well as throughout the entire 16 week treatment period.

The dispensed weight of sponsor-provided TCS tubes for the two different potencies (low and moderate) varies between countries due to different supply regions. Average weights of full tubes were used to determine the dispensed weights for each region. Returned tubes were weighed with cap (without the carton) to determine the amount of TCS in grams (g) used at each visit.

For low potency TCS, the dispensed tube weight with cap (without the carton) in Japan is 13.5g. For countries supplied by European distributors (Czech Republic, Denmark, France, Germany, Italy, and Russia), the dispensed weight of low potency TCS is 21g. The remaining countries, supplied by US distributors (India, Mexico, and Taiwan), the weight of low potency TCS is 40 g.
For moderate potency TCS, the dispensed tube weight with cap (without the carton) in Japan is 13.5g. For countries supplied by European distributors, the dispensed weight of moderate potency TCS is 38g. The remaining countries, supplied by US distributors, the weight of moderate potency TCS is 40g.

If a returned tube is not weighed or not returned then the tube can be classified as partially used, fully used, unused, or unknown. Partially used rescue medication tubes will be defined as 50% used whereas fully used and unused tubes will be defined as 100% and 0% used respectively. When drug accountability is not performed for a particular tube of rescue medication or an answer of ‘unknown’ is given for a tube which is not returned, that particular tube will not be included in the analysis.

The number of days rescue therapy is used for each patient is also collected on the diary device. The proportion of time that the patients did not use rescue therapy will be summarized for the aforementioned visit intervals by potency (low or moderate) and both potencies combined. For this analysis, the date of the first entry on the diary device will be used to signify the first day of rescue therapy use.

Additionally, a summary of the initial rescue therapy and the reason for requiring initial rescue will be produced, as well as a summary of the proportion of patients rescued at each study visit. A summary of all rescue medications will be provided.

### 6.10. Previous and Concomitant Therapy

Summaries of previous and concomitant medications will be based on the ITT population.

At screening, previous and current AD treatments are recorded for each patient. Concomitant therapy for the treatment period is defined as therapy that starts before or during the treatment period and ends during the treatment period or is ongoing (has no end date or ends after the treatment period). Should there be insufficient data to make this comparison (for example, the concomitant therapy stop year is the same as the treatment start year, but the concomitant therapy stop month and day are missing), the medication will be considered as concomitant for the treatment period.

Summaries of previous medications will be as follows:

- Previous AD therapies

Summaries of concomitant medications will be as follows:

- Concomitant medications excluding rescue medicine

### 6.11. Efficacy Analyses

The general methods used to summarize efficacy data, including the definition of baseline value for assessments are described in Section 6.2. The censoring rules applied to data as well as imputation methods are described in Section 6.4.
Table JAHL.6.4 provides the descriptions and derivations of the primary, secondary, and exploratory efficacy outcomes.

Table JAHL.6.5 provides the detailed analyses including analysis type, method and imputation, population, time point, and comparisons for efficacy analyses.
<table>
<thead>
<tr>
<th>Measure</th>
<th>Description</th>
<th>Variable</th>
<th>Derivation / Comment</th>
<th>Imputation Approach if Missing Components</th>
</tr>
</thead>
<tbody>
<tr>
<td>Validated Investigator’s Global Assessment for AD (IGA)</td>
<td>The validated investigator’s global assessment of the patient’s overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear) to 4 (severe). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.</td>
<td>IGA score</td>
<td>Single item. Range: 0 to 4 0 represents “clear” 4 represents “severe”</td>
<td>Single item, missing if missing.</td>
</tr>
<tr>
<td></td>
<td>Change from baseline in IGA score</td>
<td>Change from baseline: observed IGA score − baseline IGA score</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• IGA [0,1] with ≥2-point improvement</td>
<td>• Observed score of 0 or 1 and change from baseline ≤-2</td>
<td></td>
<td>▪ Missing if baseline or observed value is missing.</td>
</tr>
<tr>
<td></td>
<td>• IGA [0]</td>
<td>• Observed score of 0</td>
<td></td>
<td>▪ Single item, missing if missing.</td>
</tr>
<tr>
<td>Eczema Area and Severity Index (EASI)</td>
<td>The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis – disease extent and clinical signs (Hanifin et al 2001) – by scoring the extent of disease (percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (erythema, edema/papulation, excoriation, and lichenification) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2 and 3. Each body site will have a score that ranges from 0 to 72, and the final EASI score will be obtained by weight-averaging these 4 scores. Hence, the final EASI score will range from 0 to 72 for each time point.</td>
<td>EASI score</td>
<td>Derive EASI region score for each of head and neck, trunk, upper limbs, and lower limbs as follows: EASI_{region} = (Erythema + edema/papulation + Excioration + Lichenification) <em>(value from percentage involvement), where erythema, edema/papulation, excoriation, and lichenification are evaluated on a scale of 0 to 3 and value from percentage involvement is on a scale of 0 to 6. Then total EASI score is as follows: EASI = 0.1</em>EASI_{head and neck} + 0.3<em>EASI_{trunk} + 0.2</em>EASI_{upper limbs} + 0.4*EASI_{lower limbs}.</td>
<td>N/A – partial assessments cannot be saved.</td>
</tr>
<tr>
<td></td>
<td>• Change from baseline in EASI score</td>
<td>Change from baseline: observed EASI score − baseline EASI score</td>
<td></td>
<td>Missing if baseline or observed value is missing.</td>
</tr>
</tbody>
</table>
|                              | • Percent change from baseline EASI score                                     | % change from baseline: \[
\frac{\text{Observed score} - \text{Baseline}}{\text{Baseline}} \times 100
\] |                                                                                       |                                           |
<p>|                              | EASI50                                                                       | % Improvement in EASI score from baseline ≥ 50%                  |                                                                                       | Missing if baseline or observed value is missing. |</p>
<table>
<thead>
<tr>
<th><strong>Body Surface Area (BSA) Affected by AD</strong></th>
<th><strong>BSA score</strong></th>
<th><strong>Change from baseline in BSA score</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Body surface area affected by AD will be assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region will be assessed for disease extent ranging from 0% to 100% involvement. The overall total percentage will be reported based off of all 4 body regions combined, after applying specific multipliers to the different body regions to account for the percent of the total BSA represented by each of the 4 regions.</td>
<td>Use the percentage of skin affected for each region (0 to 100%) in EASI as follows: $\text{BSA Total} = 0.1\times\text{BSA}<em>{\text{head and neck}} + 0.3\times\text{BSA}</em>{\text{trunk}} + 0.2\times\text{BSA}<em>{\text{upper limbs}} + 0.4\times\text{BSA}</em>{\text{lower limbs}}$</td>
<td>Change from baseline: observed BSA score – baseline BSA score</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>SCORing Atopic Dermatitis (SCORAD)</strong></th>
<th><strong>SCORAD score</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>The SCORing Atopic Dermatitis (SCORAD) index uses the rule of nines to assess disease extent (head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; and genitals 1%). It evaluates 6 clinical characteristics to determine disease severity: (1) erythema,</td>
<td>$\text{SCORAD} = \frac{A}{5} + \frac{7B}{2} + C$, where A is extent of disease, range 0-100 B is disease severity, range 0-18 C is subjective symptoms, range 0-20</td>
<td>Missing if components A and B are missing or if component C is missing. Partial assessments performed by physician cannot be saved and partial assessments performed by subject cannot be saved.</td>
</tr>
</tbody>
</table>
(2) edema/papulation, (3) ooze/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss in the last 72 hours on visual analogue scales (VAS) of 0 to 10 where 0 is no itch or sleep loss and 10 is worst imaginable itch or sleep loss. These 3 aspects: extent of disease, disease severity, and subjective symptoms combine to give a maximum possible score of 103 (Stalder et al. 1993; Kunz et al. 1997; Schram et al. 2012).

<table>
<thead>
<tr>
<th></th>
<th>Change from baseline in SCORAD score</th>
<th>Change from baseline: observed SCORAD score – baseline SCORAD score</th>
<th>% change from baseline: ( \frac{Observed\ score - Baseline}{Baseline} \times 100 )</th>
<th>Missing if baseline or observed value is missing.</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCORAD75</td>
<td>% Improvement in SCORAD from baseline ≥75%:</td>
<td>% change from baseline ≤-75</td>
<td>Missing if baseline or observed value is missing.</td>
<td></td>
</tr>
<tr>
<td>SCORAD90</td>
<td>% Improvement in SCORAD from baseline ≥90%:</td>
<td>% change from baseline ≤-90</td>
<td>Missing if baseline or observed value is missing.</td>
<td></td>
</tr>
<tr>
<td>Measure</td>
<td>Variable</td>
<td>Analysis Method (Section 6.2.3)</td>
<td>Population (Section 6.2.3)</td>
<td>Comparison/Time Point</td>
</tr>
<tr>
<td>---------</td>
<td>----------</td>
<td>---------------------------------</td>
<td>----------------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>Validated Investigator’s Global Assessment for AD (IGA)</td>
<td>Proportion of patients achieving IGA [0,1] with a ≥2-point improvement</td>
<td>Logistic regression using NRI</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg vs PBO; Week 16</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Bari 1-mg vs PBO; Week 16</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PPS</td>
<td>Bari 4-mg or Bari 2-mg vs Bari 1-mg vs PBO; Week 16</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 4</td>
</tr>
<tr>
<td></td>
<td>Proportion of patients achieving IGA [0]</td>
<td>Logistic regression using pMI and Tipping Point</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 16</td>
</tr>
<tr>
<td>Eczema Area and Severity Index (EASI)</td>
<td>• EASI score</td>
<td>MMRM</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 16</td>
</tr>
<tr>
<td></td>
<td>• Change from baseline in EASI score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Percent change from baseline in EASI score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ANCOVA using mLOCF</td>
<td>PPS</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 16</td>
<td></td>
</tr>
<tr>
<td></td>
<td>pMI and Tipping Point</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 16</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Proportion of patients achieving EASI50</td>
<td>Logistic regression using NRI</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 16</td>
</tr>
<tr>
<td></td>
<td>• Proportion of patients achieving EASI75</td>
<td>Logistic regression using NRI</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 16</td>
</tr>
<tr>
<td></td>
<td>• Proportion of patients achieving EASI90</td>
<td>Logistic regression using NRI</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 16</td>
</tr>
<tr>
<td>Body Surface Area (BSA) Affected by AD</td>
<td>• BSA score</td>
<td>MMRM</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 16</td>
</tr>
<tr>
<td></td>
<td>• Change from baseline in BSA score</td>
<td>ANCOVA using mLOCF</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 16</td>
</tr>
<tr>
<td>Measure</td>
<td>Variable</td>
<td>Analysis Method (Section 6.2.3)</td>
<td>Population (Section 6.2.1)</td>
<td>Comparison/Time Point</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>---------------------------------</td>
<td>----------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>SCORing</td>
<td>SCORAD score</td>
<td>MMRM</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO: Week 16</td>
</tr>
<tr>
<td>Atopic Dermatitis (SCORAD)</td>
<td>Change from baseline in SCORAD score</td>
<td>ANCOVA using mLOCF</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO: Week 16</td>
</tr>
<tr>
<td></td>
<td>Percent change from baseline in SCORAD score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proportion of patients achieving</td>
<td>SCORAD75</td>
<td>Logistic regression using NRI</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO: Week 16</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Logistic regression using pMI</td>
<td>PPS</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO: Week 16</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Logistic regression using NRI</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO: Week 16</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>pMI and Tipping Point</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO: Week 16</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin Infections</td>
<td>Proportion of patients developing skin infections requiring antibiotic treatment</td>
<td>Fisher’s exact</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO: Week 16</td>
</tr>
</tbody>
</table>

Abbreviations: ANCOVA = analysis of covariance; Bari = baricitinib; ITT = intent-to-treat; mLOCF = modified last observation carried forward; MMRM = mixed model repeated measures; NRI = nonresponder imputation; PBO = placebo; pMI=placebo multiple imputation; PPS = per protocol set.
6.11.1. Primary Outcome and Methodology

The validated Investigator’s Global Assessment for AD (IGA) uses the clinical characteristics of erythema, papulation/induration, oozing/crusting and lichenification to produce a single-item score ranging from 0 to 4. The primary analysis of the study is to test the null hypotheses that neither baricitinib 4-mg nor baricitinib 2-mg is superior to placebo when evaluating the proportion of patients achieving IGA of 0 or 1 at Week 16 in the ITT population. The analysis assumes that treatment response disappears after patients are rescued or permanently discontinue from treatment. This will serve as the primary estimand. In this estimand, missing data due to the application of the primary censoring rule and the occurrence of other non-censor intercurrent events will be imputed using the NRI method described in Section 6.4.1.

A supplemental estimand is to test the null hypotheses that neither baricitinib 4-mg nor baricitinib 2-mg is superior to placebo when evaluating the proportion of patients achieving IGA of 0 or 1 at Week 16 in the ITT population. This analysis assumes the treatment response disappears after patients permanently discontinue from treatment. In this supplemental estimand, missing data due to the application of the secondary censoring rule and the occurrence of other non-censor intercurrent events will be imputed using the method described in Table JAHL.6.1.

A logistic regression analysis as described in Section 6.2.3 will be used for the comparisons. The odds ratio, the corresponding 95% CIs and p-value, as well as the treatment differences and the corresponding 95% CIs, will be reported.

Multiplicity controlled analyses will be performed on the primary and key secondary (see Section 4.2.1) objectives to control the overall Type I error rate at a 2-sided alpha level of 0.05. A graphical approach will be used to perform the multiplicity controlled analyses as described in Section 6.6.

6.11.2. Secondary and Exploratory Efficacy Analyses

For secondary analysis, the null hypotheses is that neither baricitinib 4-mg nor baricitinib 2-mg is superior to placebo in the ITT population. These analyses assume treatment response disappears after patients are rescued or permanently discontinued from treatment and will serve as the primary estimand. In this estimand, missing data due to the application of the primary censoring rule and the occurrence of other non-censor intercurrent events will be imputed using the method described in Table JAHL.6.1.

A supplemental estimand for secondary endpoints is to test the null hypotheses that neither baricitinib 4-mg nor baricitinib 2-mg is superior to placebo in the ITT population. These analyses assumes the treatment response disappears after patients permanently discontinue from treatment. In this supplemental estimand, missing data due to the application of the secondary censoring rule and the occurrence of other non-censor intercurrent events will be imputed using the method described in Table JAHL.6.1.
A list of exploratory endpoints are provided in Section 4.2.2. There will be no adjustment for multiple comparisons for exploratory endpoints. The secondary and exploratory efficacy endpoints are detailed in Table JAHL.6.4 and analyses are provided in Table JAHL.6.5. Health outcomes analyses are described in Section 6.12.

### 6.11.3. Sensitivity Analyses

Sensitivity analyses are included to demonstrate robustness of analyses methods using different missing data imputations, censoring rules, populations and analyses assumptions. Sensitivity analyses for select outcomes have been previously described and include the following:

- Analyses of key endpoints using the per-protocol analysis set (Section 6.2.1)
- Analyses of key endpoints using the secondary censoring rule (Section 6.2)
- Placebo multiple imputation (Section 6.4.4)
- Tipping point analysis (Section 6.4.5)
- The addition of a treatment-by-region interaction to the logistic regression model for the primary outcome (Section 6.5)
- Analysis of continuous outcomes with ANCOVA (Section 6.2.3), with missing data imputed using mLOCF (Section 6.4.3).


The general methods used to summarize health outcomes and quality-of-life measures, including the definition of baseline value for assessments are described in Section 6.1.

Health outcomes and quality-of-life measures will generally be analyzed according to the formats discussed in Section 6.11.

Table JAHL.6.6 includes the descriptions and derivations of the health outcomes and quality-of-life measures.

Table JAHL.6.7 provides the detailed analyses including analysis type, method and imputation, population, time point, and comparisons for health outcomes and quality-of-life measures.

Additional psychometric analyses will be performed by Global Patient Outcomes Real World Evidence at Lilly and documented in a separate analysis plan.
<table>
<thead>
<tr>
<th>Measure</th>
<th>Description</th>
<th>Variable</th>
<th>Derivation / Comment</th>
<th>Imputation Approach if Missing Components</th>
</tr>
</thead>
<tbody>
<tr>
<td>Itch Numeric Rating Scale (NRS)</td>
<td>The Itch Numeric Rating Scale (NRS) is a patient-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing “no itch” and 10 representing “worst itch imaginable.” Overall severity of a patient’s itching is indicated by selecting the number that best describes the worst level of itching in the past 24 hours (Naegeli et al. 2015; Kimball et al. 2016). Refer to Section 6.2.2 for details on how to calculate the weekly score which will be used in the continuous analysis.</td>
<td>Itch NRS score</td>
<td>Single item; range 0-10. Refer to Section 6.2.2 on how to derive the visit score.</td>
<td>Refer to Section 6.2.2 on how to derive the weekly visit score.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Change from baseline in Itch NRS</td>
<td>Missing if baseline or observed value is missing.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Percent change from baseline in Itch NRS</td>
<td>Missing if baseline is missing or &lt;4 or observed value is missing.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Change from baseline: observed Itch score – baseline Itch score</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>% change from baseline:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>100 × (\frac{\text{Observed score} - \text{Baseline}}{\text{Baseline}})</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Change from baseline ≤4 and baseline ≥4</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Itch-free days (Itch NRS = 0)</td>
<td>If patients do not have at least 16 non-missing assessments in each 4-week interval, the score is missing.</td>
</tr>
<tr>
<td>Skin Pain Numeric Rating Scale (NRS)</td>
<td>Skin Pain NRS is a patient-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing “no pain” and 10 representing “worst pain imaginable.” Overall severity of a patient’s skin pain is indicated by selecting the number that best describes the worst level of skin pain in the</td>
<td>Skin Pain NRS score</td>
<td>Single item; range 0 to 10. Refer to Section 6.2.2 on how to derive the visit score.</td>
<td>Refer to Section 6.2.2 on how to derive the visit score.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Change from baseline in Skin Pain NRS</td>
<td>Missing if baseline or observed value is missing.</td>
</tr>
<tr>
<td>Measure</td>
<td>Description</td>
<td>Variable</td>
<td>Derivation / Comment</td>
<td>Imputation Approach if Missing Components</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
<td>----------</td>
<td>----------------------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>past 24 hours</td>
<td>Refer to Section 6.2.2 for details on how to calculate the weekly score which will be used in the continuous analysis.</td>
<td>Pain-free days (Skin pain NRS = 0)</td>
<td>Count of observed value = 0 for 28-day (4-week) intervals starting on the day of the first study drug administration. This will be calculated for the following visit intervals: baseline to Week 4, Week 4 to Week 8, Week 8 to Week 12 and Week 12 to Week 16. Thus, if Day 1 is defined as the day of first study drug administration, the baseline to Week 4 assessment is based on Day 1 to Day 28, Week 4 to Week 8 is based on Day 29 to Day 56, etc.</td>
<td>If patients do not have at least 16 non-missing assessments in each 4-week interval, the score is missing.</td>
</tr>
</tbody>
</table>
| Atopic Dermatitis Sleep Scale (ADSS) | The Atopic Dermatitis Sleep Scale (ADSS) is a 3-item, patient-administered questionnaire developed to assess the impact of itching on sleep including difficulty falling asleep, frequency of waking, and difficulty getting back to sleep last night. Patients rate their difficulty falling asleep and difficulty getting back to sleep, items 1 and 3, respectively, using a 5-point Likert-type scale with response options ranging from 0 “not at all” to 4 “very difficult.” Patients report their frequency of waking last night, item 2, by selecting the number of times they woke up each night, ranging from 0 to 29 times. The ADSS is designed to be completed each day with respondents thinking about sleep “last night.” Each item is scored individually. | - Item 1 score of ADSS
- Item 2 score of ADSS
- Item 3 score of ADSS | Single items: Item 1, range 0 to 4; Item 2, range 0 to 29; Item 3, range 0 to 4. | Refer to Section 6.2.2 on how to derive the visit score. |
| | | - Change from baseline in score of Item 1 of ADSS
- Change from baseline in score of Item 2 of ADSS
- Change from baseline in score of Item 3 of ADSS | Change from baseline: observed ADSS item score – baseline ADSS item score | Missing if baseline or observed value is missing. |
<table>
<thead>
<tr>
<th>Measure</th>
<th>Description</th>
<th>Variable</th>
<th>Derivation / Comment</th>
<th>Imputation Approach if Missing Components</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient-Oriented Eczema Measure (POEM)</td>
<td>The POEM is a simple, 7-item, patient-administered scale that assesses disease severity in children and adults. Patients respond to questions about the frequency of 7 symptoms (itching, sleep disturbance, bleeding, weeping/oozing, cracking, flaking, and dryness/roughness) over the last week. Response categories include “No days,” “1-2 days,” “3-4 days,” “5-6 days,” and “Every day” with corresponding scores of 0, 1, 2, 3, and 4, respectively. Scores range from 0-28 with higher total scores indicating greater disease severity (Charman et al. 2004).</td>
<td>POEM score</td>
<td>POEM total score: sum of questions 1 to 7. Range 0 to 28.</td>
<td>If a single question is left unanswered, then that question is scored as 0. If more than one question is unanswered, then the tool is not scored. If more than one response is selected, then the response with the highest score is used.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Change from baseline in POEM score</td>
<td>Change from baseline: observed POEM score – baseline POEM score</td>
<td>Missing if baseline or observed value is missing.</td>
</tr>
<tr>
<td>Patient Global Impression of Severity–Atopic Dermatitis (PGI-S-AD)</td>
<td>The Patient Global Impression of Severity–Atopic Dermatitis (PGI-S-AD) is a single-item question asking the patient how they would rate their overall AD symptoms over the past 24 hours. The 5 categories of responses range from “no symptoms” to “severe.”</td>
<td>PGI-S-AD score</td>
<td>Single item. Range 1 to 5. Refer to Section 6.2.2 on how to derive the visit score.</td>
<td>Refer to Section 6.2.2 on how to derive the visit score.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Change from baseline in PGI-S-AD</td>
<td>Change from baseline: observed PGI-S-AD score – baseline PGI-S-AD score</td>
<td>Missing if baseline or observed value is missing.</td>
</tr>
<tr>
<td>Hospital Anxiety Depression Scale (HADS)</td>
<td>The Hospital Anxiety Depression Scale (HADS) is a 14-item self-assessment scale that determines the levels of anxiety and depression that a patient is experiencing.</td>
<td>HADS score for anxiety and depression domains</td>
<td>Anxiety domain score is sum of the seven anxiety questions, range 0 to 21; Depression domain score is sum of the seven depression questions, range 0 to 21.</td>
<td>N/A – partial assessments cannot be saved.</td>
</tr>
<tr>
<td>Measure</td>
<td>Description</td>
<td>Variable</td>
<td>Derivation / Comment</td>
<td>Imputation Approach if Missing Components</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>-------------------------------------------</td>
</tr>
<tr>
<td>Dermatology Life Quality Index (DLQI)</td>
<td>The Dermatology Life Quality Index (DLQI) is a simple, patient-administered, 10-item, validated, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The recall period of this scale is over the “last week.” Response categories include “a little,” “a lot,” and “very much,” with corresponding scores of 1, 2, and 3, respectively, and “not at all,” or unanswered (“not relevant”) responses scored as 0. Scores range from 0-30 with higher scores indicating greater impairment of quality of life. A DLQI total score of 0 to 1 is considered as having no effect on a patient’s health-related QoL (Hongbo et al. 2005), and a 4-point change from baseline is considered as the minimal clinically important difference threshold (Khilji et al. 2002; Basra et al. 2015).</td>
<td>Symptoms and feelings domain</td>
<td>Sum of questions 1 and 2, range 0 to 6.</td>
<td>N/A – partial assessments cannot be saved.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Daily activities domain</td>
<td>Sum of questions 3 and 4, range 0 to 6.</td>
<td>N/A – partial assessments cannot be saved.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Leisure domain</td>
<td>Sum of questions 5 and 6, range 0 to 6.</td>
<td>N/A – partial assessments cannot be saved.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Work and school domain</td>
<td>Sum of questions 7 and 7B (if it is answered), range 0 to 3. Responses of “yes” and “no” on Question 7 are given scores of 3 and 0 respectively. If Question 7 is answered “no” then Question 7b is answered with “a lot”, “a little”, “not at all” getting scores of 2, 1, 0 respectively.</td>
<td>N/A – partial assessments cannot be saved.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Personal relationships domain</td>
<td>Sum of questions 8 and 9, range 0 to 6.</td>
<td>N/A – partial assessments cannot be saved.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Treatment domain</td>
<td>Question 10, range 0 to 3.</td>
<td>N/A – partial assessments cannot be saved.</td>
</tr>
<tr>
<td>Measure</td>
<td>Description</td>
<td>Variable</td>
<td>Derivation / Comment</td>
<td>Imputation Approach if Missing Components</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
<td>----------</td>
<td>----------------------</td>
<td>--------------------------------------------</td>
</tr>
<tr>
<td>DLQI total score</td>
<td>DLQI total score: sum of all six DLQI domain scores, range 0 to 30.</td>
<td>N/A – partial assessments cannot be saved.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline in DLQI</td>
<td>Change from baseline: observed DLQI score – baseline DLQI score</td>
<td>Missing if baseline or observed value is missing.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Work Productivity and Activity Impairment: Atopic Dermatitis (WPAI-AD)**

The Work Productivity and Activity Impairment Questionnaire—Atopic Dermatitis (WPAI-AD) records impairment due to AD during the past 7 days. The WPAI-AD consists of 6 items grouped into 4 domains: absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment. Scores are calculated as impairment percentages (Reilly et al. 1993), with higher scores indicating greater impairment and less productivity.

<table>
<thead>
<tr>
<th>Employment status</th>
<th>Question (Q1)</th>
<th>Single item, missing if missing.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in employment status</td>
<td>Employed at baseline and remained employed: Q1 = 1 at post-baseline visit and at baseline visit. Not employed at baseline and remain unemployed: Q1 = 0 at post-baseline visit and at baseline visit.</td>
<td>Missing if baseline or observed value is missing.</td>
</tr>
<tr>
<td>Percentage of absenteeism</td>
<td>Percent work time missed due to problem: ( \frac{(Q2/(Q2+Q4))}{100} )</td>
<td>If Q2 or Q4 is missing, then missing.</td>
</tr>
<tr>
<td>Change from baseline in absenteeism</td>
<td>Change from baseline: observed absenteeism – baseline absenteeism</td>
<td>Missing if baseline or observed value is missing.</td>
</tr>
<tr>
<td>Percentage of presenteeism</td>
<td>Percent impairment (reduced productivity while at work) while working due to problem: ( \frac{(Q5/10)}{100} )</td>
<td>If Q5 is missing, then missing.</td>
</tr>
<tr>
<td>Change from baseline in presenteeism</td>
<td>Change from baseline: observed presenteeism – baseline absenteeism</td>
<td>Missing if baseline or observed value is missing.</td>
</tr>
<tr>
<td>Overall work impairment</td>
<td>Percent overall work impairment (combines absenteeism and presenteeism) due to problem: ( \frac{(Q2/(Q2+Q4)) + [(1-Q2/(Q2+Q4))\cdot(Q5/10))}{100} )</td>
<td>If Q2, Q4, or Q5 is missing, then missing.</td>
</tr>
<tr>
<td>Change from baseline in work impairment</td>
<td>Change from baseline: observed work impairment – baseline work impairment</td>
<td>Missing if baseline or observed value is missing.</td>
</tr>
<tr>
<td>Measure</td>
<td>Description</td>
<td>Variable</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Percentage of impairment in activities</td>
<td></td>
<td>Percent activity impairment (performed outside of work) due to problem: fixtures / tools removed &lt;br&gt; (Q6/10) * 100</td>
</tr>
<tr>
<td>Change from baseline in impairment in activities</td>
<td></td>
<td>Change from baseline: observed impairment in activities &lt;br&gt; baseline impairment in activities</td>
</tr>
<tr>
<td>European Quality of Life–5 Dimensions–5 Levels (EQ-5D-5L)</td>
<td>The European Quality of Life–5 Dimensions–5 Levels (EQ-5D-5L) is a standardized measure of health status that provides a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of 2 components: a descriptive system of the respondent’s health and a rating of his or her current health state using a 0 to 100 mm VAS. The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The respondent is asked to indicate his or her health state by ticking (or placing a cross) in the box associated with the most appropriate statement in each of the 5 dimensions. It should be noted that the numerals 1 to 5 have no arithmetic properties and should not be used as an ordinal score. The VAS records the respondent’s self-rated health on a vertical VAS where the endpoints are labeled “best imaginable health state” and “worst imaginable health state.” This information can be used as a quantitative measure of</td>
<td>EQ-5D mobility &lt;br&gt; EQ-5D self-care &lt;br&gt; EQ-5D usual activities &lt;br&gt; EQ-5D pain/discomfort &lt;br&gt; EQ-5D anxiety/depression &lt;br&gt; EQ-5D VAS &lt;br&gt; EQ-5D-5L UK Population-based index score (health state index)</td>
</tr>
<tr>
<td>EQ-5D-5L US Population-based index score</td>
<td>Derive EQ-5D-5L US Population-based index score &lt;br&gt; EQ-5D-5L US Population-based index score</td>
<td>Need to derive EQ-5D-5L US Population-based index score &lt;br&gt; EQ-5D-5L US Population-based index score</td>
</tr>
</tbody>
</table>
### Measure: Nocturnal Sleep-Wake and Itch Patterns

An actigraphy device, a hypoallergenic device worn on the wrist, will be used to collect sleep-wake patterns and quantify nocturnal scratching events. Each patient will be dispensed 2 actigraphy devices. One will be worn on the wrist at all times and the other will be worn only during hours of sleep (one on each wrist).

Analyses for sleep-wake patterns will include: total sleep time (min), wake after sleep onset (WASO) (min), and sleep efficiency (%). Analyses for nocturnal scratching will include: scratching events (#), scratching duration (s), scratching events per hour (#/h), scratching duration per hour (s/h), and time from first to last scratching event (h).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Derivation / Comment</th>
<th>Imputation Approach if Missing Components</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sleep:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total sleep time (min)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wake after sleep onset (WASO) (min)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sleep efficiency (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scratching:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scratching events (#)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scratching duration (s)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scratching events per hour (#/h)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scratching duration per hour (s/h)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time from first to last scratching event (h)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Change from baseline in sleep-wake and itch patterns | Change from baseline: observed score – baseline score | Missing if baseline or observed value is missing |

Time from first to last scratching event = Time of last scratching event – time of first scratching event. Otherwise, single items.

Refer to Section 6.2.2 on how to derive the visit score.
<table>
<thead>
<tr>
<th>Measure</th>
<th>Variable</th>
<th>Analysis Method (Section 6.2.3)</th>
<th>Population (Section 6.2.1)</th>
<th>Comparison/Time Point</th>
<th>Analysis Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Itch Numeric Rating Scale (NRS)</td>
<td>• Itch NRS score</td>
<td>MMRM</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 4, 16</td>
<td>Secondary Analysis</td>
</tr>
<tr>
<td></td>
<td>• Change from baseline in Itch NRS score</td>
<td>ANCOVA using mLOCF</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 4, 16</td>
<td>Sensitivity Analysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>pMI</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 4, 16</td>
<td>Sensitivity Analysis</td>
</tr>
<tr>
<td>Percent change from baseline Itch score</td>
<td></td>
<td>MMRM</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 1, 16</td>
<td>Secondary Analysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ANCOVA using mLOCF</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 1, 16</td>
<td>Sensitivity Analysis</td>
</tr>
<tr>
<td>Proportion of patients achieving a 4-point</td>
<td>Logistic regression using NRI</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 1, 2, 4, 16</td>
<td>Key Secondary Analysis</td>
<td></td>
</tr>
<tr>
<td>improvement in Itch NRS in subgroup of</td>
<td>Logistic regression using pMI and Tipping Point</td>
<td>PPS</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 16</td>
<td>Sensitivity analysis</td>
<td></td>
</tr>
<tr>
<td>patients who had baseline Itch NRS ≥4</td>
<td></td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 16</td>
<td>Sensitivity analysis</td>
<td></td>
</tr>
<tr>
<td>Number of Itch-free (Itch NRS = 0) Days</td>
<td>Descriptive statistics</td>
<td>ITT</td>
<td>No comparisons; Week 12 to 16</td>
<td>Exploratory Analysis</td>
<td></td>
</tr>
<tr>
<td>Skin Pain Numeric Rating Scale (NRS)</td>
<td>• Skin Pain NRS score</td>
<td>MMRM</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 16</td>
<td>Key Secondary Analysis</td>
</tr>
<tr>
<td></td>
<td>• Change from baseline in Skin Pain NRS score</td>
<td>ANCOVA using mLOCF</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 16</td>
<td>Sensitivity Analysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>pMI</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 16</td>
<td>Sensitivity Analysis</td>
</tr>
<tr>
<td>Number of Skin Pain-free (Skin pain NRS = 0)</td>
<td>Descriptive statistics</td>
<td>ITT</td>
<td>No comparisons; Week 12 to 16</td>
<td>Exploratory Analysis</td>
<td></td>
</tr>
<tr>
<td>Measure</td>
<td>Variable</td>
<td>Analysis Method (Section 6.2.3)</td>
<td>Population (Section 6.2.1)</td>
<td>Comparison/Time Point</td>
<td>Analysis Type</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>---------------------------------</td>
<td>-----------------------------</td>
<td>------------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>Atopic Dermatitis Sleep Scale (ADSS)</td>
<td>• ADSS item scores&lt;br&gt;• Change from baseline in ADSS item scores</td>
<td>MMRM</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 1, 16</td>
<td>Key Secondary Analysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PPS</td>
<td></td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 16</td>
<td>Sensitivity analysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ANCOVA using mLOCF</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 16</td>
<td>Sensitivity analysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>pMI</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 16</td>
<td>Sensitivity analysis</td>
</tr>
<tr>
<td>Patient-Oriented Eczema Measure (POEM)</td>
<td>• POEM score&lt;br&gt;• Change from baseline in POEM score</td>
<td>MMRM</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 16</td>
<td>Secondary Analysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ANCOVA using mLOCF</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 16</td>
<td>Sensitivity analysis</td>
</tr>
<tr>
<td>Patient Global Impression of Severity-Atopic Dermatitis (PGI-S-AD)</td>
<td>• PGI-S-AD score&lt;br&gt;• Change from baseline in PGI-S-AD score</td>
<td>MMRM</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 16</td>
<td>Secondary Analysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ANCOVA using mLOCF</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 16</td>
<td>Sensitivity analysis</td>
</tr>
<tr>
<td>Hospital Anxiety Depression Scale (HADS)</td>
<td>• HADS domain scores&lt;br&gt;• Change from baseline in HADS domain</td>
<td>MMRM</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 16</td>
<td>Secondary Analysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ANCOVA using mLOCF</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 16</td>
<td>Sensitivity Analysis</td>
</tr>
<tr>
<td>Dermatology Life Quality Index (DLQI)</td>
<td>• DLQI total score&lt;br&gt;• Change from baseline in DLQI&lt;br&gt;• Observed and change from baseline in domain scores&lt;br&gt;-Symptoms and feelings&lt;br&gt;-Daily activities&lt;br&gt;-Leisure&lt;br&gt;-Work and school&lt;br&gt;-Personal relationships&lt;br&gt;-Treatment</td>
<td>MMRM</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 16</td>
<td>Secondary Analysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ANCOVA using mLOCF</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO; Week 16</td>
<td>Sensitivity Analysis</td>
</tr>
<tr>
<td>Measure</td>
<td>Variable</td>
<td>Analysis Method (Section 6.2.3)</td>
<td>Population (Section 6.2.1)</td>
<td>Comparison/Time Point</td>
<td>Analysis Type</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>---------------------------------</td>
<td>---------------------------</td>
<td>-----------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Work Productivity and Activity Impairment:</td>
<td>Observed and Change from baseline in employment status</td>
<td>Descriptive statistics (observed)</td>
<td>ITT</td>
<td>No comparisons; Week 16</td>
<td>Secondary Analysis</td>
</tr>
<tr>
<td>Atopic Dermatitis (WPAI-AD)</td>
<td>Observed and Change from baseline in:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• absenteeism</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• presenteeism</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• overall work impairment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• impairment in activities</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>European Quality of Life–5 Dimensions–5</td>
<td>Observed values in</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levels (EQ-5D-5L)</td>
<td>• EQ-5D mobility</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• EQ-5D self-care</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• EQ-5D usual activities</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• EQ-5D pain/discomfort</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• EQ-5D anxiety/depression</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Observed and Change from baseline in</td>
<td>MMRM</td>
<td>ITT</td>
<td>Bari 4-mg or Bari 2-mg or Bari 1-mg vs PBO: Week 16</td>
<td>Secondary Analysis</td>
</tr>
<tr>
<td></td>
<td>• EQ-5D VAS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• EQ-5D-5L UK Population-based index score</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• EQ-5D-5L US Population-based index score</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nocturnal Itch assessed by Actigraphy Device</td>
<td>• Nocturnal Sleep-Wake and Itch scores:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Change from baseline in Nocturnal Sleep-Wake and Itch scores:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Total sleep time (min)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Wake after sleep onset (WASO) (min)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Sleep efficiency (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Scratching events (#)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Scratching duration (s)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Scratching events per hour (#/h)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Scratching duration per hour (s/h)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Time from first to last scratching event (h)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Abbreviations: ANCOVA = analysis of covariance; Bari = baricitinib; ITT = intent-to-treat; mLOCF = modified last observation carried forward; MMRM = mixed model repeated measures; NRI = nonresponder imputation; PBO = placebo; pMI = placebo multiple imputation; PPS = per protocol set.
6.13. Bioanalytical and Pharmacokinetic/Pharmacodynamic Methods
Pharmacokinetic (PK), Pharmacodynamic (PD) and Biomarker analyses to address secondary and exploratory objectives of this study will be described by Lilly in separate PK/PD and Biomarker analysis plans.

The general methods used to summarize safety data, including the definition of baseline value are described in Section 6.2.

Safety analyses will include data before and after rescue, unless otherwise stated, and patients will be analyzed according to the investigational product to which they were randomized at Visit 2. A sensitivity approach to the safety analyses will use data censored at last dose of the study drug for patients rescued to systemic therapy. These analyses will be conducted for treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), AEs leading to permanent study drug discontinuation and special topics excluding deaths and malignancies. Additional analyses may be conducted using data after rescue to systemic therapy for some safety topics such as systemic TEAEs, and SAEs. Safety analyses will take place using the safety population defined in Section 6.2.1.

Safety topics that will be addressed include the following: AEs, clinical laboratory evaluations, vital signs and physical characteristics, Columbia Suicide Severity Rating Scale (C-SSRS), the Self-Harm Supplement Form, safety in special groups and circumstances, including adverse events of special interest (AESI) (see Section 6.14.5), and investigational product interruptions.

Unless otherwise specified, by-visit summaries will include planned on-treatment visits. For tables that summarize events (such as AEs, categorical lab abnormalities, shift to maximum value), post-last dose follow-up data will be included. Follow-up data is defined as all data occurring up to 30 days (planned maximum follow-up time) after last dose of treatment including rescue, regardless of study period. Listings will include all safety data.

For selected safety assessments other than events, descriptive statistics may be presented for the last measure observed during post-treatment follow-up (up to 30 days after the last dose of treatment including rescue, regardless of study period).

6.14.1. Extent of Exposure
Duration of exposure (in days) will be calculated as follows:

- Duration of exposure to investigational product (including exposure after the initiation of rescue therapy): \(\text{date of last dose of study drug including rescue} - \text{date of first dose of study drug} + 1\).

Last dose of study drug including rescue is calculated as last date on study drug. For patients discontinuing study drug or study due to the reason ‘Lost to Follow-up’, the duration of exposure is calculated as \(\text{date of to second last visit} - \text{date of first dose of study drug} + 1\).
Total patient-years (PY) of exposure to study drug will be reported for each treatment group for overall duration of exposure. Descriptive statistics will be provided for patient-days of exposure and the frequency of patients falling into different exposure ranges in addition to cumulative exposures will be summarized.

Exposure ranges will be summarized as follows:

- ≥28 days, ≥56 days, ≥84 days, and ≥112 days
- >0 to <28 days, ≥28 days to <56 days, ≥56 days to <84 days, ≥84 days to <112 days, and ≥112 days

Overall exposure for a treatment group will be summarized in total PY which is calculated according to the following formula:

\[
\text{Exposure in PYE} = \frac{\text{sum of duration of exposure in days}}{365.25}
\]

### 6.14.2. Adverse Events

Adverse events are recorded in the eCRFs. Each AE will be coded to system organ class (SOC) and preferred term (PT) using the Medical Dictionary for Regulatory Activities (MedDRA) version that is current at the time of database lock. Severity of AEs is recorded as mild, moderate, or severe.

A TEAE is defined as an event that either first occurred or worsened in severity after the first dose of study treatment and on or prior to the last visit date during the analysis period. The analysis period is defined as the treatment period plus 30 days off-drug follow-up time.

Adverse events are classified based upon the MedDRA PT. The MedDRA Lowest Level Term (LLT) will be used in defining which events are treatment-emergent. The maximum severity for each LLT during the baseline period up to first dose of the study medication will be used as baseline. If an event with missing severity is preexisting during the baseline period, and persists during the treatment period, then the baseline severity will be considered mild for determining treatment-emergence (that is, the event is treatment-emergent if the severity is moderate or severe postbaseline and not treatment-emergent if the severity is mild postbaseline). If an event occurring postbaseline has a missing severity, then the event is considered treatment-emergent unless the baseline is severe, in which case the event is not treatment-emergent. The day and time for events where onset is on the day of the first dose of study treatment will both be used to distinguish between pretreatment and posttreatment to derive treatment-emergence. Should there be insufficient data for AE start date to make this comparison (for example, the AE start year is the same as the treatment start year, but the AE start month and day are missing), the AE will be considered treatment-emergent.

In general, summaries will include the number of patients in the safety population (N), frequency of patients experiencing the event (n), and relative frequency (that is, percentage; n/N*100). For any events that are gender-specific based on the displayed PT, the denominator used to compute the percentage will only include patients from the appropriate gender.
For events of special interest, a more robust incidence rate, IR per 100 patient-years of observation (PYO) may be provided. Patient-years of observation will be calculated as the sum of all patient observation time in the treatment group. For a patient with an event, the observation time will be censored at the event date; for a patient without the event, the observation time will be counted until the end of the analysis period.

PYO will be calculated as follows:

$$PYO = \sum_{pt \ w \ event} \frac{\text{event start date} - \text{first trt dose date} + 1}{365.25} + \sum_{pt \ w/o \ event} \frac{\text{last observation date} - \text{first trt dose date} + 1}{365.25}$$

IR will be calculated as follows:

$$IR = \frac{\text{number of patients with event}}{PYO} \times 100$$

For each IR provided, a Poisson Distribution 95% CI will be calculated. Treatment group comparisons will be provided based on the incidence rate difference (IRD) together with its 95% CI.

In an overview table, the number and percentage of patients in the safety population who experienced death, an SAE, any TEAE, discontinuation from the study due to an AE, permanent discontinuation from study drug due to an AE, or a severe TEAE will be summarized by treatment group.

The number and percentage of patients with TEAEs will be summarized by treatment group in 2 formats:

- by MedDRA PT nested within SOC with decreasing frequency in SOC, and events ordered within each SOC by decreasing frequency in the baricitinib 4-mg group;
- by MedDRA PT with events ordered by decreasing frequency in the baricitinib 4-mg group.

### 6.14.2.1. Common Adverse Events

Common TEAEs are defined as TEAEs that occurred in ≥2% (before rounding) of patients in any treatment group including placebo. The number and percentage of patients with common TEAEs will be summarized by treatment using MedDRA PT ordered by decreasing frequency in the baricitinib 4-mg group.

The number and percentage of patients with TEAEs will be summarized by maximum severity by treatment using MedDRA PT ordered by decreasing frequency in the baricitinib 4-mg group for the common TEAEs. For each patient and TEAE, the maximum severity for the MedDRA level being displayed is the maximum postbaseline severity observed from all associated LLTs mapping to that MedDRA PT.
6.14.2.2. Serious Adverse Event Analyses
Consistent with the International Conference on Harmonisation (ICH) E2A guideline (1994) and 21 Code of Federal Regulations (CFR) 312.32 (a) (2010), a SAE is any AE that results in any one of the following outcomes:

- Death
- Initial or prolonged inpatient hospitalization
- A life-threatening experience (that is, immediate risk of dying)
- Persistent or significant disability/incapacity
- Congenital anomaly/birth defect

The number and percentage of patients who experienced any SAE will be summarized by treatment using MedDRA PT nested within SOC. Events will be ordered by decreasing frequency in the baricitinib 4-mg group within decreasing frequency in SOC. The SAEs will also be summarized by treatment using MedDRA PT without SOC.

An individual listing of all SAEs will be provided. A listing of deaths, regardless of when they occurred during the study, will also be provided.

6.14.2.3. Other Significant Adverse Events
Other significant AEs to be summarized will provide the number and percentage of patients who

- permanently discontinued study drug because of an AE or death;
- temporarily interrupted study drug because of AE;

by treatment using MedDRA PT nested within SOC. Events will be ordered by decreasing frequency in the baricitinib 4-mg group within decreasing frequency in SOC.

A summary of temporary interruptions of study drug will also be provided, showing the number of patients who experienced at least one temporary interruption and the number of temporary interruptions per patient with an interruption. Further, the duration of each temporary interruption (in days), the cumulative duration of dose interruption (in days) using basic descriptive statistics and the reason for dose interruption will be provided.

A listing of all AEs leading to permanent discontinuation from the study drug or from the study will be provided. A listing of all temporary study drug interruptions, including interruptions for reasons other than AEs, will be provided.

6.14.2.4. Criteria for Notable Patients
Patient narratives will be provided for all patients who experience certain “notable” events prior to data cutoff for the submission. See compound level safety standards for list of criteria.

6.14.3. Clinical Laboratory Evaluation
For the categorical laboratory analyses (shift and treatment emergent), the analysis period is defined as the treatment period plus 30 days off-drug follow-up time. The analysis period for the continuous laboratory analyses (e.g., change from baseline) is defined as the treatment period excluding off-drug follow-up time.
All laboratory tests will be presented using the International Système (SI) and US conventional (CN) units. The performing central laboratory reference ranges will be used to define the low and high limits. Key results pertaining to the 4 key hepatic laboratory assessments (alanine aminotransferase [ALT], aspartate aminotransferase [AST], total bilirubin, and alkaline phosphatase [ALP]) will be included as a separate analysis to address the risk of liver injury as a special safety topic (see Section 6.14.5.1).

There is one special circumstance for laboratory values to be derived based on regularly scheduled, protocol-specified analytes. The low-density lipoprotein/high-density lipoprotein (LDL/HDL) ratio will be derived as the ratio of LDL cholesterol to HDL cholesterol. There are no central lab reference ranges for the LDL/HDL ratio.

The following will be conducted for the laboratory analytes collected quantitatively:

- **Box plots:** Values at each visit (starting at randomization) and change from last baseline to each visit and to last postbaseline measure will be displayed in box plots for patients who have both a baseline and at least 1 postbaseline visit. The last non-missing observation in the treatment period will be used as the last observation. Individual measurements outside of reference limits will also be displayed using distinct symbols overlaying the box plot. Original-scale data will be used for the display but for some analytes (for example, immunoglobulins) a logarithmic scale will be used to aid in viewing the measures of central tendency and dispersion. Unplanned measurements will be excluded. Descriptive summary statistics will be included below the box plot along with p-values resulting from between treatment comparison in change from last baseline to last observation. An ANCOVA model with explanatory term for treatment and the baseline value as a covariate will be used. These box plots will be used to evaluate trends over time and to assess a potential impact of outliers on central tendency summaries.

- **Treatment-emergent high/low analyses:** The number and percentage of patients with treatment-emergent high and low laboratory results at any time will be summarized by treatment group. Planned and unplanned measurements will be included. A treatment-emergent high result is defined as a change from a value less than or equal to the high limit at all baseline visits to a value greater than the high limit at any time during the treatment period. A treatment-emergent low result is defined as a change from a value greater than or equal to the low limit at all baseline visits to a value less than the low limit at any time during the treatment period. The Fisher’s exact test will be used for the treatment comparisons.

For laboratory analyte measurements collected qualitatively, a listing of abnormal findings will be provided. The listing will include but not be limited to patient ID, treatment group, laboratory collection date, analyte name, and analyte finding. If needed by the safety physician/scientist, the number and percentage of patients with treatment-emergent abnormal laboratory results at any time will be summarized by treatment. Planned and unplanned measurements will be included. A treatment-emergent abnormal result is defined as a change from normal at all baseline visits to abnormal at any time postbaseline.
The listing of specific reference ranges used in analysis of laboratory data will be provided. Note that additional analyses of certain laboratory analytes will be discussed within sub-sections of Section 6.14.5 pertaining to Special Safety topics (Section 6.14.5.1 for hepatic analytes, Section 6.14.5.2 for analytes related to hematological changes, Section 6.14.5.3 for analytes related to lipids, Section 6.14.5.4 for analytes related to renal function, and Section 6.14.5.5 for CPK).

6.14.4. Vital Signs and Other Physical Findings

For the treatment-emergent categorical analyses (shift and treatment emergent), the analysis period is defined as the treatment period plus 30 days off-drug follow-up time. The analysis period for the continuous analyses (e.g., change from baseline) is defined as the treatment period excluding off-drug follow-up time.

Vital signs and physical characteristics include systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse, weight, and BMI. Original-scale data will be analyzed. When these parameters are analyzed as continuous numerical variables, unplanned measurements will be excluded. When these parameters are analyzed as categorical outcomes and/or treatment-emergent abnormalities, planned and unplanned measurements will be included.

The planned analyses described for the laboratory analytes in Section 6.14.3 will be used to analyze the vital signs and physical characteristics.

Table JAHL.6.8 defines the low and high baseline values as well as the criteria used to define treatment-emergence based on post-baseline values. The blood pressure and pulse rate criteria are consistent with the document Selected Reference Limits for Pulse/Heart Rate, Arterial Blood Pressure (Including Orthostasis), and Electrocardiogram Numerical Parameters for Use in Analyses of Phase 2-4 Clinical Trials Version 1.3 approved on April 29, 2015 as recommended by the Lilly Cardiovascular Safety Advisory Committee (CVSAC).

<table>
<thead>
<tr>
<th>Parameter (Units of Measure)</th>
<th>Low</th>
<th>High</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systolic Blood Pressure (mm Hg)</td>
<td>≤90 (low limit) and decrease from lowest value during baseline ≥20 if &gt;90 at each baseline visit</td>
<td>≥140 (high limit) and increase from highest value during baseline ≥20 if &lt;140 at each baseline visit</td>
</tr>
<tr>
<td>Diastolic Blood Pressure (mm Hg)</td>
<td>≤50 (low limit) and decrease from lowest value during baseline ≥10 if &gt;50 at each baseline visit</td>
<td>≥90 (high limit) and increase from highest value during baseline ≥10 if &lt;90 at each baseline visit</td>
</tr>
<tr>
<td>Pulse (beats per minute)</td>
<td>&lt;50 (low limit) and decrease from lowest value during baseline ≥15 if ≥50 at each baseline visit</td>
<td>&gt;100 (high limit) and increase from highest value during baseline ≥15 if ≤100 at each baseline visit</td>
</tr>
<tr>
<td>Weight (kilograms)</td>
<td>(Loss) decrease ≥7% from lowest value during baseline</td>
<td>(Gain) increase ≥7% from highest value during baseline</td>
</tr>
</tbody>
</table>
6.14.5. Special Safety Topics, including Adverse Events of Special Interest

In addition to general safety parameters, safety information on specific topics of special interest will also be presented. Additional special safety topics may be added as warranted. The topics outlined in this section include the protocol-specified AESI.

In general, for topics regarding safety in special groups and circumstances, patient profiles and/or patient listings, where applicable, will be provided when needed to allow medical review of the time course of cases/events, related parameters, patient demographics, study drug treatment and meaningful concomitant medication use. In addition to the safety topics for which provision or review of patient data is specified, these will be provided when summary data are insufficient to permit adequate understanding of the safety topic.

6.14.5.1. Abnormal Hepatic Tests

Analyses for abnormal hepatic tests will involve 4 laboratory analytes: ALT, AST, total bilirubin, and ALP. In addition to the analyses described in Section 6.14.3, this section describes specific analyses for this topic.

First, the number and percentage of patients with the following abnormal elevations in hepatic laboratory tests at any time will be summarized between treatment groups:

- The percentages of patients with an ALT measurement $\geq 3\times$, $5\times$, and $10\times$ the central laboratory ULN during the treatment period will be summarized for all patients with a postbaseline value and for subsets based on various levels of baseline.
  - The analysis of $3\times$ ULN will contain 4 subsets: patients whose non-missing maximum baseline value is $\leq 1\times$ ULN, patients whose maximum baseline is $>1\times$ ULN but $<3\times$ ULN, patients whose maximum baseline value is $\geq 3\times$ ULN, and patients whose baseline values are missing.
  - The analysis of $5\times$ ULN will contain 5 subsets: patients whose non-missing maximum baseline value is $\leq 1\times$ ULN, patients whose maximum baseline is $>1\times$ ULN but $<3\times$ ULN, patients whose maximum baseline is $\geq 3\times$ ULN but $<5\times$ ULN, patients whose maximum baseline value is $\geq 5\times$ ULN, and patients whose baseline values are missing.
  - The analysis of $10\times$ ULN will contain 6 subsets: patients whose non-missing maximum baseline value is $\leq 1\times$ ULN, patients whose maximum baseline is $>1\times$ ULN but $<3\times$ ULN, patients whose maximum baseline is $\geq 3\times$ ULN but $<5\times$ ULN, patients whose maximum baseline is $\geq 5\times$ ULN but $<10\times$ ULN, patients whose maximum baseline value is $\geq 10\times$ ULN, and patients whose baseline values are missing.
- The percentages of patients with an AST measurement $\geq 3\times$, $5\times$, and $10\times$ the central laboratory ULN during the treatment period will be summarized for all patients with a postbaseline value and for subsets based on various levels of baseline. Analyses will be constructed as described above for ALT.
• The percentages of patients with a total bilirubin measurement ≥2× the central laboratory ULN during the treatment period will be summarized for all patients with a postbaseline value and subset into 4 subsets: patients whose non-missing maximum baseline value is ≤1× ULN, patients whose maximum baseline is >1× ULN but <2× ULN, patients whose maximum baseline value is ≥2× ULN, and patients whose baseline values are missing.

• The percentages of patients with an ALP measurement ≥1.5× the central laboratory ULN during the treatment period will be summarized for all patients with a postbaseline value and subset into 4 subsets: patients whose non-missing maximum baseline value is ≤1× ULN, patients whose maximum baseline is >1× ULN but <1.5× ULN, patients whose maximum baseline value is ≥1.5× ULN, and patients whose baseline values are missing.

Information collected from additional hepatic safety data collection forms will be provided in patient profiles.

Second, to further evaluate potential hepatotoxicity, an Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH) plot will be created for all patients whether treated with baricitinib and/or other treatment using the whole study period(s). Each patient with at least 1 postbaseline ALT and total bilirubin will be included in the eDISH; therefore, a patient could contribute 1 or more points to the plot. The points correspond to maximum total bilirubin and maximum ALT, even if not obtained from the same blood draw. Scheduled and unscheduled measures will be used. Another eDISH plot will be provided where maximum AST is used in place of maximum ALT. A listing of patients potentially meeting Hy’s rule will be provided (defined as ≥3× ULN for ALT or AST, and ≥2× ULN for total bilirubin, not necessarily at the same time).

When criteria are met for hepatic evaluation and completion of the hepatic safety CRF, investigators are required to answer a list of questions (see Compound level safety standards). A listing of the collected information will be generated together with a graphical patient profile. This includes demographics, disposition, and a display of study drug exposure, AEs, medications, and the liver-related measurements over time will be provided for these patients and any additional patients meeting ALT or AST measurement greater than or equal to 5× ULN (on a single measurement) or ALP measurement greater than or equal to 2× ULN (on a single measurement).

6.14.5.2. Hematologic Changes
Hematologic changes will be defined based on clinical laboratory assessments. Common Terminology Criteria for Adverse Events will be applied for selected laboratory tests and are described in the compound level safety standards. These CTCAE grading schemes are consistent with both Version 3.0 and Version 4.03 of the CTCAE guidelines (CTCAE 2003, 2010).

Treatment-emergent laboratory abnormalities occurring at any time during the treatment period and shift tables of baseline to maximum grade during the treatment period will be tabulated. Planned and unplanned measurements will be included. Treatment-emergence will be characterized using the following 5 criteria (as appropriate to the grading scheme):

• any increase in postbaseline CTCAE grade from worst baseline grade
• increase to Grade 1 or above at worst postbaseline
• increase to Grade 2 or above at worst postbaseline
• increase to Grade 3 or above at worst postbaseline
• increase to Grade 4 at worst postbaseline.

Shift tables will show the number and percentage of patients based on baseline to maximum during the treatment period, with baseline depicted by the most extreme grade during the baseline period. With each shift table, a shift table summary displaying the number and percentage of patients with maximum postbaseline results will be presented by treatment group for each treatment period within the following categories:

• Decreased: postbaseline category < baseline category,
• Increased: postbaseline category > baseline category,
• Same: postbaseline category = baseline category.

A laboratory-based treatment-emergent outcome related to increased platelet count will be summarized in similar fashion. Treatment-emergent thrombocytosis as a laboratory-based abnormality will be defined as an increase in platelet count from a maximum baseline value \( \leq 600 \text{ billion/L} \) to any postbaseline value >600 billion/L (Lengfelder et al. 1998). Planned and unplanned measurements will be included.

A listing of patients with treatment-emergent thrombocytosis may be provided for safety review.

6.14.5.3. Lipids Effects

Lipids effects will be assessed through analysis of elevated total cholesterol, elevated LDL cholesterol, decreased HDL cholesterol, and elevated triglycerides as described in Section 6.14.3 and with TEAEs potentially related to hyperlipidemia.

Categorical analyses will be performed using National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guidelines (2002) as shown in the compound level safety standards. The grade-like categories shown in this table are ordered from traditionally most desirable to least desirable for the purposes of these analyses.

Shift tables will show the number and percentage of patients based on baseline to the least desirable category during the treatment period, with baseline depicted by the least desirable category during the baseline period. With each shift table, a shift table summary displaying the number and percentage of patients with the least desirable postbaseline results will be presented by treatment group for each treatment period within the following categories:

• Decreased: postbaseline category more desirable than baseline category,
• Increased: postbaseline category less desirable than baseline category,
• Same: postbaseline category = baseline category.

Treatment-emergent laboratory abnormalities related to elevated total cholesterol, elevated triglycerides, elevated LDL cholesterol, and decreased and increased HDL cholesterol occurring at any time during the treatment period will be tabulated using the NCEP categories shown in the compound level safety standards.
Treatment-emergent elevated total cholesterol will be characterized as follows:

- increase to categories ‘Borderline high’ or ‘High’
- increase to category ‘High’.

Treatment-emergent elevated triglycerides will be characterized as

- increase to categories ‘Borderline high,’ ‘High,’ or ‘Very high’
- increase to categories ‘High’ or ‘Very high’
- increase to category ‘Very high’.

Treatment-emergent elevated LDL cholesterol will be characterized as

- increase to categories ‘Borderline high,’ ‘High,’ or ‘Very high’
- increase to categories ‘High’ or ‘Very high’
- increase to ‘Very high’.

Treatment-emergent abnormal HDL cholesterol will be characterized as

- decreased
  - decrease to categories ‘Normal’ or ‘Low’
  - decrease to category ‘Low’
- increased
  - increase to categories ‘Normal’ or ‘High’
  - increase to category ‘High’.

The percentages of patients with treatment-emergent potential hyperlipidemia will be summarized by treatment, ordered by decreasing frequency in the baricitinib 4-mg group using a predefined MedDRA list of PTs that is a subset of the narrow scope PTs in the MedDRA SMQ ‘Dyslipidemia’ (code 200000026) [see Compound level safety standards].

6.14.5.4. Renal Function Effects

Effects on renal function will be assessed through analysis of elevated creatinine.

Common Terminology Criteria for Adverse Events will be applied for laboratory tests related to renal effects as shown in the compound level safety standards. This CTCAE grading scheme is consistent with both Version 3.0 and Version 4.03 of the CTCAE guidelines. Shift tables will show the number and percentage of patients based on baseline to maximum during the treatment period, with baseline depicted by highest grade during the baseline period. Treatment-emergent laboratory abnormalities related to elevated creatinine occurring at any time during the treatment period will be tabulated. Refer to the Compound level safety standards for details.

6.14.5.5. Elevations in Creatine Phosphokinase (CPK)

Elevations in creatine phosphokinase (CPK) will be addressed using CTCAE criteria as shown in the compound level safety standards. This CTCAE grading scheme is consistent with both Version 3.0 and Version 4.03 of the CTCAE guidelines. Analyses will be the same as the CTCAE analyses specified for laboratory tests related to renal function events in Section 6.14.5.2.
A listing of elevated CPK (CTCAE grade of 3 or above) will be provided for medical safety review.

Treatment-emergent adverse events potentially related to muscle symptoms may be analyzed, based on reported AEs. The Muscle Symptoms special search category is a pre-defined MedDRA search criteria list that contains the narrow scope terms from the Rhabdomyolysis / myopathy SMQ (code 20000002) plus selected terms from the Musculoskeletal SOC. These terms are shown in the compound level safety standards.

6.14.5.6. Infections

Infections will be defined using all the PTs from the Infections and Infestations SOC as defined in MedDRA. Serious infection will be defined as all the infections that meet the SAE criteria.

The number and percentage of patients with TEAEs of infections, serious infections, and infections resulting in permanent study drug discontinuation will be summarized by treatment group using MedDRA PTs. The proportion of patients developing skin infections requiring antibiotic treatment by Week 16 will also be summarized on the overview of infections table.

The number and percentage of patients with TEAEs of infections by maximum severity will be summarized by treatment group using MedDRA PTs.

Treatment-emergent infections will be reviewed in context of other clinical and laboratory parameters via a listing (details see Compound level safety standards).

The TEAE infections will be further analyzed in terms of potential opportunistic infection, herpes zoster and herpes simplex. Summary of HBV DNA monitoring results and association between infection and neutropenia/lymphopenia will also be provided in the context of infections.

Opportunistic infection

To identify potential opportunistic infections (POIs), the following approach will be used:

- identifying the POIs using a list of MedDRA PTs (refer to the compound level safety standards).

POIs identified through these search approaches may be combined in one list for medical assessment and final classification of whether the case met the modified Winthrop definitions for OI. A final listing for OIs will be provided for the CSR and to assist the composition of patient narratives.

Herpes zoster

Cases of herpes zoster will be further classified as follows:

- localized or non-multidermatomal-involvement of the primary and/or adjacent dermatomes only
o complicated – documented ocular (cornea or deeper structure; for example, iritis, keratitis, retinitis, etc.) or motor nerve involvement (e.g., palsy; post herpetic neuralgia [PHN] does not meet criteria for motor nerve involvement).

• uncomplicated-localized or non-multidermatomal cases that are not complicated

• multidermatomal-involvement beyond primary and adjacent dermatomes (that is, >3 contiguous dermatomes) or involvement of two or more non-contiguous dermatomes
  o complicated-ocular (cornea or deeper structure; for example iritis, keratitis, retinitis, etc.) or motor nerve involvement
  o uncomplicated-multidermatomal cases that are not complicated

• disseminated-systemic infection, widespread, often bilateral with or without internal organ involvement (i.e., visceral involvement) and other systemic signs/symptoms.

• Recurrent - >1 infection occurring in an individual patient during the course of participation in the baricitinib clinical program.

All herpes zoster will undergo medical review to determine the classification as described above.

A summary of herpes zoster table will be provided. The summary table will also include event maximum severity, seriousness, whether resulting in temporary study drug interruption, whether resulting in study drug discontinuation, whether treated with antiviral medication, and event outcome. The incidence rate adjusted for observation time will also be provided (as defined in Section 6.14.2). Of note, in the context of herpes zoster, antiviral medication treatment is defined as that the medication was initiated at the event start date, or within 30 days before or after the event start date. The antiviral medication for herpes zoster includes but not limited to Aciclovir, Brivudine, Cidofovir, Famciclovir, Foscarnet, Ganciclovir, Penciclovir, Valaciclovir, Valganciclovir, Vidarabine (best presented by J05AB, J05AC, J05AE, and J05AH ATC codes).

For specific data lock, medical representatives will review the concomitant medication list and make adjustment of the above list if necessary.

If a patient has more than 1 event of herpes zoster, the event with the maximum severity will be used in these summary tables. If more than 1 event of herpes zoster occurs with the same severity, the event with the longest duration will be used in the summary table.

**Herpes simplex**

A summary analysis of herpes simplex will be provided. Herpes simplex will be defined based on MedDRA PT as listed in the compound level safety standards (both narrow and broad terms in the herpes simplex section). The list needs to be reviewed by GPS/medical prior to data locks (final and interim). The summary table will also include event maximum severity, seriousness, whether resulting in temporary study drug interruption, whether resulting in study drug discontinuation, and whether treated with antiviral medication. The exposure-adjusted incidence rate (EAIR) will also be provided.

If a patient has more than 1 event of herpes simplex, the event with the maximum severity will be used in these summary tables. If more than 1 event of herpes simplex occurs with the same severity, the event with the longest duration will be used in the summary table.
Skin Infections

A summary analysis of skin infections will be provided. Skin infections will be defined based on MedDRA preferred term as listed in Compound level safety standards.

HBV DNA

A listing of patients with detectable hepatitis B virus (HBV) deoxyribonucleic acid (DNA) post baseline will be provided.

HBV DNA status post baseline (not detectable, detectable but not quantifiable [i.e., LLOD], quantifiable [i.e., LLOD]) will be summarized by treatment group stratified by baseline HBV serology status, specifically:

- HBsAb+ / HBcAb+
- HBsAb- / HBcAb+

Association between infection and neutropenia/lymphopenia

To evaluate the association between infection and neutropenia, for the controlled analysis sets, the frequency of infections will be provided by patient subgroups defined by the worst CTCAE grades of neutropenia during the analysis period, respectively. Infection outcomes considered for this analysis are any treatment-emergent infection, serious infection and herpes zoster. For this analysis, no statistical comparison will be provided.

In addition, and depending on the number of cases with CTCAE Grade 2 or greater, a summary table will be provided for treatment-emergent infections that were preceded or accompanied by neutropenia. For this analysis, neutropenia is defined as (1) CTCAE Grade 2 or greater, (2) Grade 3 or greater. Infection events with onset date ≤14 days before or after the Grade 2 neutrophil count collection date will be considered as infections preceded or accompanied by neutropenia.

Similar analyses as above will be conducted to evaluate the association between infection and lymphopenia.

6.14.5.7. Major Adverse Cardiovascular Events (MACE) and Other Cardiovascular Events

Potential major adverse cardiovascular events (MACE) and other cardiovascular events requiring adjudication will be analyzed.

Categories and subcategories analyzed will include, but are not limited to, the following:

- MACE
  - Cardiovascular death,
  - Myocardial infarction (MI),
  - Stroke,
- Other cardiovascular events
  - Transient ischemic attack,
  - Hospitalization for unstable angina,
Hospitalization for heart failure,
- Serious arrhythmia,
- Resuscitated sudden death,
- Cardiogenic shock,
- Coronary interventions (such as coronary artery bypass surgery or percutaneous coronary intervention),
- Non-cardiovascular death,
- All-cause death.

In general, events requiring adjudication are documented by investigative sites using an endpoint reporting CRF. This CRF is then sent to the adjudication center which uses an adjudication reporting CRF to document the final assessment of the event as a MACE, as some other cardiovascular event, or as no event (according to the Clinical Endpoint Committee Charter). In some cases, however, the investigator may not have deemed that an event had met the endpoint criteria but the event was still sent for adjudication as a potential MACE, other cardiovascular event, or no event. These events are included in the adjudication process to ensure adequate sensitivity. In these instances, the adjudication reporting CRF will not have a matching endpoint reporting CRF from the investigator. Events generated from these circumstances will be considered as events sent for adjudication in the absence of an investigator’s endpoint reporting form.

The number and percentage of patients with MACE, other cardiovascular events, non-cardiovascular death, and all-cause death, as positively adjudicated, will be summarized by treatment group based on the categories and subcategories above.

A listing of the events sent for adjudication will be provided to include data concerning the MedDRA PT related to the event, the seriousness of the event, and the event outcome, along with the adjudicated result.

6.14.5.8. Venous and Pulmonary Artery Thromboembolic (VTE) Events

Events identified as representative of venous thromboembolic events (VTE) disease will be classified as Deep Vein Thrombosis (DVT), pulmonary embolism (PE), or other peripheral venous thrombosis and will be analyzed. The following definitions apply:

- **DVT:** Clinical diagnosis of a thrombosis in a deep vein above the knee that must be confirmed by objective evidence of either: a filling defect of deep veins of the leg on venography or a non-compressible venous segment on ultrasound or confirmation by other imaging modality (e.g., Computed tomography [CT], Magnetic Resonance Imaging [MRI]).
- **PE:** Clinical diagnosis of pulmonary embolus that must be confirmed by objective evidence of either: a filling defect of pulmonary arteries by either pulmonary angiography or CT angiography or by a high probability Ventilation Perfusion (VQ) scan.
- **Other Peripheral Venous Thrombosis:** Clinical diagnosis of a venous thrombosis not specified by either DVT or PE above. Other peripheral venous thrombosis disease must
be confirmed by objective evidence by imaging including venography, ultrasound, CT scan, or MRI. Examples of these would include thrombi in calf (i.e., below the knee), portal vein, subclavian vein, or mesenteric vein. Superficial thrombophlebitis alone is not considered a VTE event.

- Other peripheral venous thromboses of the lower limbs: DVT (above knee) and non-superficial below knee thromboses will also be summarized.

In general, events requiring adjudication are documented by investigative sites using an endpoint reporting CRF. Refer to Section 6.14.5.7 for more details as the process is the same as that of MACE.

The number and percentage of patients with a VTE according to the 4 classifications defined above, as positively adjudicated, will be summarized by treatment group.

A listing of the VTE events sent for adjudication will be provided to include data concerning the MedDRA PT related to the event, the seriousness of the event, and the event outcome, along with the adjudicated result.

6.14.5.9. Arterial Thromboembolic (ATE) Events
Refer to the Compound level safety standards.

6.14.5.10. Malignancies
Malignancies will be identified using terms from the malignant tumors SMQ (SMQ 20000194). Malignancies excluding non-melanoma skin cancers (NMSC) and NMSC will be reported separately.

All the cases identified by malignant tumors SMQ will be assessed by GPS/medical team to determine confirmed NMSC cases.

First, a listing including all the malignancy cases will be prepared before database lock along with the planned NMSC flag according to the following MedDRA version 21.1 PTs (the list will be updated depending on the MedDRA version used for analysis):

- Squamous cell carcinoma of skin (10041834)
- Bowen’s disease (10006059)
- Basal cell carcinoma (10004146)
- Basosquamous carcinoma (10004178)
- Basosquamous carcinoma of skin (10004179)
- Squamous cell carcinoma (10041823)
- Skin squamous cell carcinoma metastatic (10077314)
- Skin cancer (10040808)
- Carcinoma in situ of skin (10007390)
- Keratoacanthoma (10023347).
- Cutaneous lymphoma (10079945)
- Vulvar squamous cell hyperplasia (10079905).
This internal review is to be done prior to database lock. The case review and subsequent summary analyses will include all the cases reported in the study database or by LSS report, disregarding the length of gap between the last treatment dose date and the event date. The NMSC flag will be confirmed by Global Product Safety (GPS)/medical team during the internal review process.

The number and percentage of patients with TEAEs associated malignancies excluding NMSC and NMSC will be summarized by treatment group.

6.14.5.11. Allergic Reactions/Hypersensitivities
A search will be performed using the MedDRA version 21.1 SMQs to search for relevant events, using the following queries:

- Anaphylactic reaction SMQ (20000021)
- Hypersensitivity SMQ (20000214)
- Angioedema SMQ (2000024)

Assessment of the Anaphylactic reaction SMQ includes an algorithmic query. An algorithmic case comprises one or more events associated with an individual administration of study drug, where the events include:

- A narrow term from the SMQ (Category A of the SMQ);
- Multiple terms from the SMQ, comprising terms from at least two of the following categories from the SMQ:
  - Category B - (Upper Airway/Respiratory)
  - Category C - (Angioedema/Urticaria/Pruritus/Flush)
  - Category D - (Cardiovascular/Hypotension).

In the present studies, where study drug is administered daily, events will be considered as associated with an individual administration of study drug when the events are reported on the same study day.

Events that satisfy the queries will be listed, by temporal order within patient ID, and will include SOC, PT, SMQ event categorization including detail on the scope (narrow, algorithmic or broad), reported AE term, AE onset and end dates, severity, seriousness, outcome, etc.

In addition, a summary table will be provided. Refer to the Compound safety level standards for details.

Treatment-emergent adverse events related to potential gastrointestinal (GI) perforations will be analyzed using reported AEs. Identification of these events will be based on review of the PTs of the MedDRA SMQ 20000107, GI perforations (note that this SMQ holds only narrow terms and has no broad terms). Potential GI perforations identified by the above SMQ search will be provided as a listing for internal review by the medical safety team. Each case will be assessed to determine whether it is GI perforation. A summary table based on medical review may be provided and treatment comparisons will be made using Fisher’s exact test.
6.14.5.13. Columbia Suicide Severity Rating Scale
Suicidal ideation, suicidal behavior, and self-injurious behavior without suicidal intent, based on the C-SSRS, will be listed by patient and visit. Only patients that show suicidal ideation/behavior or self-injurious behavior without suicidal intent during treatment will be displayed along with all their ideation and behavior, even if not positive (i.e., if a patient’s answers are all ‘no’ for the C-SSRS, then that patient will not be displayed). A summary of the C-SSRS categories during treatment and a shift summary in the C-SSRS categories from baseline during treatment may be provided.

The Self-Harm Supplement Form is a single question to enter the number of suicidal behavior events, possible suicide behaviors, or nonsuicidal self-injurious behaviors. If the number of behavioral events is greater than zero, it will lead to the completion of the Self-Harm Follow-Up Form. The Self-Harm Follow-Up Form is a series of questions that provides a more detailed description of the behavior cases. A listing of the responses given on the Self-Harm Follow-Up Form will be provided.

6.15. Subgroup Analyses
Subgroup analyses comparing each dose of baricitinib to placebo will be performed on the ITT population at Week 16 using the primary censoring rule for the following:

- Proportion of patients achieving IGA 0 or 1
- Proportion of patients achieving EASI75 Response Rate
- Proportion of patients achieving Itch NRS 4-point improvement

The following subgroups, categorized into disease-related characteristics and demographic characteristics, will be evaluated:

- Patient Demographic and Characteristics Subgroups:
  - Gender (male, female)
  - Age group (<65, ≥65 years old)
  - Baseline weight: (<60 kg, ≥60 to <100 kg, ≥100 kg)
  - Baseline BMI (<25 kg/m², ≥25 to <30 kg/m², ≥30 kg/m²)
  - Race: (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other Pacific Islander, White, Multiple)
  - Baseline renal function status: impaired (eGFR <60 mL/min/1.73 m²) or not impaired (eGFR ≥60 mL/min/1.73 m²)

- Geographic Region Subgroups:
  - Region: (as defined in Table JAHL.5.1)
  - Specific regions (Europe, other)
  - Specific country (Japan, other)
  - Prior systemic therapy use (yes, no)

- Baseline Disease-Related Characteristics Subgroup
Descriptive statistics will be provided for each treatment and stratum of a subgroup as outlined, regardless of sample size. As all endpoints are categorical, subgroup analyses will be performed using logistic regression using Firth’s correction to accommodate (potential) sparse response rates. The model will include the categorical outcome as the dependent variable and baseline value (for EASI and itch), baseline severity, treatment, subgroup, and treatment-by-subgroup interaction as explanatory variables. Missing data will be imputed using NRI (Section 6.4.1). The treatment-by-subgroup interaction comparing treatment groups will be tested at the 0.1 significance level. The p-value from the logistic regression model will be reported for the interaction test and the subgroup test, unless the model did not converge. Response counts and percentages will be summarized by treatment for each subgroup category. The difference in percentages and 95% CI of the difference in percentages using the Newcombe-Wilson without continuity correction will be reported. The corresponding p-value from the Fisher’s exact test will also be produced.

In case any level of a subgroup comprises <10% of the overall sample size, only descriptive summary statistics will be provided for treatment arms, and no treatment group comparisons will be performed within these subgroup levels.

Additional subgroup analyses on efficacy may be performed as deemed appropriate and necessary.

6.16. Protocol Deviations

Protocol deviations will be tracked by the clinical team, and their importance will be assessed by key team members during protocol deviation review meetings. Out of all important protocol deviations (IPDs) identified, a subset occurring during Period 2 with the potential to affect efficacy analyses will result in exclusion from the PP population.

Potential examples of deviations include patients who receive excluded concomitant therapy, significant non-compliance with study medication (<80% of assigned doses taken, failure to take study medication and taking incorrect study medication), patients incorrectly enrolled in the study, and patients whose data are questionable due to significant site quality or compliance issues. Refer to a separate document for the important protocol deviations.

Trial Issue Management Plan includes the categories and subcategories of important protocol deviations and whether or not these deviations will result in the exclusion of patients from per protocol set.

The number and percentage of patients having IPD(s) will be summarized within category and subcategory of deviation by treatment group for Period 2 using the ITT population. Individual patient listings of IPDs will be provided. A summary of reasons patients were excluded from the PPS will be provided by treatment group.
6.17. Interim Analyses and Data Monitoring

The baricitinib AD, AA and SLE Phase 3 programs DMC is an independent expert advisory group commissioned and charged with the responsibility of evaluating cumulative safety at regular intervals. As such, the primary objective of the DMC is to monitor the safety of the subjects enrolled in the baricitinib AD, AA and SLE Phase 3 programs by reviewing the available clinical data at scheduled time points, as described in this DMC Charter, as well as on an ad hoc basis, as needed. The DMC will consist of members external to Lilly. This DMC will follow the rules defined in the DMC charter, focusing on potential and identified risks for this molecule and for this class of compounds. Data Monitoring Committee membership will include, at a minimum, specialists with expertise in dermatology, statistics, cardiology, and other appropriate specialties.

The DMC will be authorized to review unblinded results of analyses by treatment group prior to database lock, including study discontinuation data, AEs including SAEs, clinical laboratory data, vital sign data, etc. The DMC may recommend continuation of the study, as designed; temporary suspension of enrollment; or the discontinuation of a particular dose regimen or the entire study. While the DMC may request to review efficacy data to investigate the benefit/risk relationship in the context of safety observations for ongoing patients in the study, no information regarding efficacy will be communicated. Moreover, the study will not be stopped for positive efficacy results nor will it be stopped for futility. Hence, no alpha is spent. Details of the DMC, including its operating characteristics, are documented in the Baricitinib Atopic Dermatitis DMC charter and further details are given in the Interim Analysis Plan in Section 6.17.1.

Besides DMC members, a limited number of pre-identified individuals may gain access to the limited unblinded data, as specified in the unblinding plan, prior to the interim or final database lock, for preparation of regulatory documents. Information that may unblind the study during the analyses will not be reported to study sites or blinded study team until the study has been unblinded.

6.17.1. Interim Analysis Plan

Analyses for the DMC will include listings and/or summaries of the following information:

- patient disposition, demographics, and baseline characteristics
- concomitant medications
- exposure
- AEs, to include the following:
  - TEAEs
  - SAEs, including deaths
  - selected special safety topics
- clinical laboratory results
- vital signs
- Columbia-Suicide Severity Rating Scale
Summaries will include TEAEs, SAEs, special topics AEs, and treatment-emergent high and low laboratory and vital signs in terms of counts and percentages where applicable. For continuous analyses, box plots of laboratory analytes will be provided by time point and summaries will include descriptive statistics.

The DMC may request efficacy data if they feel there is value and to confirm a reasonable benefit/risk profile for ongoing patients in the studies. If efficacy data is requested, it will be mean change from baseline of EASI score. Further details are given in the DMC charter.

**6.18. Planned Exploratory Analyses**
The planned exploratory analyses are described in Sections 6.11 and 6.12. Additional exploratory analyses may be conducted such as exploring inadequate or super responders and their baseline characteristics and will be documented in a supplemental SAP. Health Technology Assessment (HTA) toolkit analyses, which may be produced, will also be documented in the supplemental SAP.

**6.19. Annual Report Analyses**
Annual report analyses, such as the Development Update Safety Report (DSUR), will be documented in a separate document.

**6.20. Clinical Trial Registry Analyses**
Additional analyses will be performed for the purpose of fulfilling the Clinical Trial Registry (CTR) requirements.

Analyses provided for the CTR requirements include a summary of AEs, provided as a dataset which will be converted to an XML file. Both SAEs and ‘Other’ AE are summarized: by treatment group, by MedDRA PT.

- An AE is considered ‘Serious’ whether or not it is a TEAE.
- An AE is considered in the ‘Other’ category if it is both a TEAE and is not serious. For each SAE and ‘Other’ AE, for each term and treatment group, the following are provided:
  - the number of participants at risk of an event
  - the number of participants who experienced each event term
  - the number of events experienced.
- Consistent with www.ClinicalTrials.gov requirements, ‘Other’ AEs that occur in fewer than 5% of patients/subjects in every treatment group may not be included if a 5% threshold is chosen (5% is the minimum threshold).
- AE reporting is consistent with other document disclosures for example, the CSR, manuscripts, and so forth.

Similar methods will be used to satisfy the European Clinical Trials Database (EudraCT) requirements.
7. Unblinding Plan

A separate JAHL Blinding / Unblinding Plan contains details of how the blind is maintained for this study.
8. References


Snaith RP. The Hospital Anxiety and Depression Scale. *Health and Quality of Life Outcomes.* 2003;1:29.


Approver: PPD
Approval Date & Time: 16-Jan-2019 15:12:03 GMT
Signature meaning: Approved